**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 29, 2024**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**CNS Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Nevada**

(State or other jurisdiction of

**001-39126**

(Commission File Number)

**82-2318545**

(I.R.S. Employer Identification No.)

incorporation or organization)

**2100 West Loop South, Suite 900**

**Houston, Texas 77027**

(Address of principal executive offices) (Zip Code)

**Registrant’s telephone number, including area code: (800) 946-9185**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

* Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
* Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
* Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
* Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |
| --- | --- | --- |
| Title of each class | Trading Symbols(s) | Name of each exchange on which registered |
| Common stock, par value $0.001 per share | CNSP | The NASDAQ Stock Market LLC |
|  |  |  |

**Item 1.01.** **Entry into a Material Definitive Agreement.**

On July 29, 2024, CNS Pharmaceuticals, Inc. (the “Company”) entered into Exclusive License Agreement and Stock Purchase Agreement (collectively, the “Cortice Agreements”) with Cortice Biosciences, Inc. (“Cortice”) pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights related to certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. The term of the license will expire, other than due to a breach of the Cortice Agreements, at the end of the royalty term with respect to any licensed product in any of the included territories, which begins upon the first commercial sale in such territory and ends on the latest of (i) ten years after such sale, (ii) the expiration of regulatory or marketing exclusivity for such licensed product in such country, or (c) the expiration of the last to expire valid patent claim in such country covering such licensed product.

Pursuant to the Cortice Agreements, the Company agreed to issue Cortice 573,368 shares of Company common stock upon the closing of the transaction, and 43,330 shares of Company common stock upon the receipt of shareholder approval of such issuance as required by the rules of the Nasdaq Stock Market. The Company also agreed to make milestone payments to Cortice in either cash or shares of Company common stock (at Cortice’s option) upon: (i) meeting the primary endpoint a pivotal trial for a licensed product – either $15.0 million or 411,132 shares of Company common stock; (ii) FDA acceptance of an New Drug Application for a licensed product – either $30.0 million or 822,264 shares of Company common stock; (iii) the first commercial sale in the United States of a licensed product – either $45.0 million or 1,233,395 shares of Company common stock; and (iv) the first commercial sale in Japan of a licensed product – either $10.0 million or 205,566 shares of Company common stock. The Company’s obligation to pay the above milestones in Company common stock is subject to the receipt of shareholder approval as required by the rules of the Nasdaq Stock Market. The Company also agreed to pay Cortice royalties on sales of licensed products of between 3.0%-7.5%. Finally, to the extent Cortice is required to pay any milestone payments to the original holder of the intellectual property rights licensed, the Company has agreed to make such payments to Cortice.

The forms of the Exclusive License Agreement and Stock Purchase Agreemet are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.

**Item 3.02.** **Unregistered Sales of Equity Securities.**

The information set forth in Item 1.01 is incorporated by reference herein. The shares of Company common stock issuable pursuant to the Cortice Agreements will be offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws.

**Item 7.01.** **Regulation FD.**

On July 30, 2024, the Company issued a press release regarding the transactions described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

2



|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Item 9.01.** | | **Financial Statements and Exhibits** | | | | |
| **(d) Exhibits** | |  |  |  |  |  |
| **Exhibit No.** | |  | **Exhibit Description** | | | |
|  |  |  |  |  |  |  |
| 10.1\* |  |  | Exclusive License Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc. | | | |
| 10.2 |  |  | Stock Purchase Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc. | | |  |
| 99.1 |  |  | Press release dated July 30, 2024 | | | |
|  |  |  |  | |  | |
| 104 |  |  | Cover page Interactive Data File (embedded within the Inline XBRL document) | | | |

* Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted. The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.

3



**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CNS Pharmaceuticals, Inc.

By: /s/ Chris Downs



Chris Downs

Chief Financial Officer

Dated: July 30, 2024

4



**Exhibit 10.1**

**EXCLUSIVE LICENSE AGREEMENT**

**FOR TPI-287**

**Between**

**CORTICE BIOSCIENCES, INC.**

**AND**

**CNS PHARMACEUTICALS, INC.**



|  |  |  |  |
| --- | --- | --- | --- |
|  | **TABLE OF CONTENTS** |  |  |
| **Article 1 Definitions** | | **Page** |  |
| 1 |  |
| **Article 2 Grant** | | 7 |  |
| 2.1 | Grant of License | 7 |  |
| 2.2 | No Implied Licenses; Negative Covenant | 7 |  |
| 2.3 | Sublicenses | 7 |  |
| **Article 3 Technology Transfer** | | 8 |  |
| 3.1 | Technology Transfer | 8 |  |
| 3.2 | Transfer, Assignment and Sale of Compound Inventory and Costs of Transfer | 9 |  |
| **Article 4 Regulatory Compliance** | | 9 |  |
| 4.1 | Ownership and Maintenance of Governmental Approvals | 9 |  |
| 4.2 | Pharmacovigilance. | 10 |  |
| 4.3 | Rights of Reference | 10 |  |
| 4.4 | Access to Manufacturers | 10 |  |
| 4.5 | Transfer of the IND | 10 |  |
| **Article 5 Development and Commercialization** | | 11 |  |
| 5.1 | Development | 11 |  |
| 5.2 | Ownership of Inventions | 11 |  |
| **Article 6 Royalties, Milestones, and Other Consideration** | | 12 |  |
| 6.1 | Obligation to Pay | 12 |  |
| 6.2 | Execution Payment | 12 |  |
| 6.3 | Milestone for Licensed Products | 12 |  |
| 6.4 | Development Based Milestone and Other Payments for Intravenous Formulation. | 12 |  |
| 6.5 | Development Based Milestone and Other Payments for Oral Formulation | 12 |  |
| 6.6 | Sales Milestones | 13 |  |
| 6.7 | Additional Milestones.. | 13 |  |
| 6.8 | Royalties on Net Sales. | 14 |  |
| 6.9 | No Multiple Royalties | 14 |  |
| 6.10 | Product Bundling and Combination | 14 |  |
| 6.11 | Place of Payment, Taxes and Conversions | 14 |  |
| 6.12 | Time for Payment; Interest | 15 |  |
| 6.13 | Royalty Reduction for Infringement | 15 |  |
| **Article 7 Reports and Records** | | 15 |  |
| 7.1 | Records and Audits | 15 |  |
| 7.2 | Royalty Statements | 16 |  |
| 7.3 | Confidential Treatment of Reports | 16 |  |

- i -



|  |  |  |  |
| --- | --- | --- | --- |
|  | **TABLE OF CONTENTS** |  |  |
| **Article 8 Patent Prosecution and Maintenance** | | **Page** |  |
| 16 |  |
| 8.1 | Prosecution and Maintenance | 16 |  |
| 8.2 | Abandonment | 17 |  |
| **Article 9 Dispute Resolution** | | 17 |  |
| 9.1 | Disputes | 17 |  |
| 9.2 | Performance to Continue | 18 |  |
| 9.3 | Determination of Patents and Other Intellectual Property | 18 |  |
| 9.4 | Statute of Limitation and Time-Based Defenses Tolled | 18 |  |
| **Article 10 Term and Termination** | | 19 |  |
| 10.1 | Term | 19 |  |
| 10.2 | Termination for Material Breach | 19 |  |
| 10.3 | Expiry of Royalty Term on a Country by Country Basis | 19 |  |
| 10.4 | Termination for Convenience | 19 |  |
| 10.5 | Consequences of Termination | 19 |  |
| 10.6 | Wind-Down by the Company | 20 |  |
| 10.7 | Partial Termination | 20 |  |
| 10.8 | Survival | 20 |  |
| 10.9 | Bankruptcy | 20 |  |
| **Article 11 Infringement and Other Actions** | | 20 |  |
| 11.1 | Notice of Infringement of IP Rights | 20 |  |
| 11.2 | Enforcement of IP Rights | 20 |  |
| 11.3 | Infringement by Licensed Product | 21 |  |
| 11.4 | Allocation of Damages Recovered | 21 |  |
| 11.5 | Cooperation | 21 |  |
| 11.6 | Limitations. | 21 |  |
| **Article 12 Representations, Warranties and Covenants** | | 21 |  |
| 12.1 | The Company’s Representations and Warranties | 21 |  |
| 12.2 | Licensor’s Representations and Warranties | 22 |  |
| 12.3 | The Company’s Covenant. | 23 |  |
| **Article 13 Indemnity** | | 23 |  |
| 13.1 | Indemnity Obligations of Licensor | 23 |  |
| 13.2 | Indemnity Obligations by the Company | 23 |  |
| 13.3 | Indemnity Procedure; Insurance | 24 |  |
| 13.4 | Exclusive Remedy | 24 |  |
| **Article 14 Use of Names and Publication** | | 24 |  |
| 14.1 | Use of Name | 24 |  |
| 14.2 | No Agency | 24 |  |
| 14.3 | Publication | 24 |  |

- ii -



|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **TABLE OF CONTENTS** |  |
| **Article 15 Confidentiality** | | **Page** |  |
| 25 |  |
| 15.1 | Confidentiality and Non-Use | 25 |  |
| 15.2 | Securities Filings | 25 |  |
| **Article 16 Miscellaneous Provisions** | | 26 |  |
| 16.1 | Assignment | 26 |  |
| 16.2 | Binding Nature and Inurnment | 26 |  |
| 16.3 | Compliance with Applicable Laws | 26 |  |
| 16.4 | Counterparts; Facsimile | 26 |  |
| 16.5 | Entire Agreement; Amendment | 26 |  |
| 16.6 | Force Majeure | 26 |  |
| 16.7 | Further Assurances | 26 |  |
| 16.8 | Interpretation | 27 |  |
| 16.9 | Law; Jurisdiction | 27 |  |
| 16.1 | No Consequential Damages; Liability Limit | 27 |  |
| 16.11 | Payments, Notices and Other Communications | 27 |  |
| 16.12 | Payment of Own Fees and Expenses | 28 |  |
| 16.13 | Severability | 28 |  |
| 16.14 | Waiver | 28 |  |

- iii -



**EXCLUSIVE LICENSE AGREEMENT FOR TPI-287**

This Exclusive License Agreement for TPI-287 (the “**Agreement**”), effective as of July 29, 2024 (the “**Effective Date**”), is entered into by and between Cortice Biosciences, Inc., a corporation duly organized and existing under the laws of the state of Delaware having a place of business at 1345 Avenue of the Americas, 42nd floor, New York, NY 10105 (the “**Licensor**”) and CNS Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the state of Delaware having a place of business at 2100 West Loop South, Suite 900, Houston, Texas 77027 (“**Company**”). Each of Licensor and the Company may be referred to herein individually as a “**Party**”, and collectively as the “**Parties**”.

**WHEREAS**, Licensor has the right, title, and interest in the Licensed Product and IP Rights granted to it in the Initial License;

**WHEREAS**, the Company is interested in obtaining an exclusive license to the Licensed Product and IP Rights; and

**WHEREAS**, Licensor wishes to grant to the Company such exclusive license rights as and to the extent provided under the terms of thisAgreement;

**NOW, THEREFORE**, in consideration of the foregoing recitals, the premises and the mutual covenants contained herein, the Parties hereto,intending to be legally bound, agree as follows:

**Article 1**

**Definitions**

For the purposes of this Agreement, the following capitalized terms, whether used in the singular or the plural, shall have the following meanings set forth below or, if not listed below, the meanings designated in places throughout this Agreement:

**1.1** **“AAA”** shall have the meaning set forth in Section 9.1.3.

**1.2** **“AAA Rule”** shall have the meaning set forth in Section 9.1.3.

**1.3** **“Action”** shall have the meaning set forth in Section 13.3.

**1.4 “Active Pharmaceutical Ingredient”** or **“API”** means the compound with the chemical structures as set forth in Schedule 1.4, which may beamended from time to time, to the extent owned or Controlled by the Licensor or that Licensor has or gains the ability to license.

**1.5 “Affiliate”** means, with respect to a particular Party, any Entity that directly or indirectly controls, is controlled by, or is under common Controlwith such Party.

1.5.1 “**Control**” means, with respect to an Affiliate, the direct or indirect control of more than fifty percent (50%) of the voting securities of an Entity or, if such Entity does not have outstanding voting securities, more than fifty percent (50%) of the directorships or similar positions with respect to such Entity.

1.5.2 “**Entity**” means any corporation, association, joint venture, partnership, trust, university, business, individual, government or political subdivision thereof, including an agency, or any other organization that can exercise independent legal standing.

- 1 -



**1.6 “Applicable Law(s)”** means the U.S. Federal Food, Drug, and Cosmetic Act and all other laws, rules, regulations and guidelines within theTerritory that apply to the import, export, research and development, manufacture, marketing, distribution or sale of the Licensed Product in the Field of Use anywhere in the Territory or the performance of a particular Party’s obligations under this Agreement (including disclosure obligations as required by the United States Securities and Exchange Commission or other comparable exchange or securities commission having authority over a Party) to the extent applicable and relevant to such Party.

**1.7** **“Arbitration Notice”** shall have the meaning set forth in Section 9.1.3.

**1.8 “CNS Indication”** means degenerative diseases of the brain and central nervous system, including Alzheimer’s Disease, but excluding oncologyindications.

**1.9 “Combination Product”** means a product containing the Licensed Product and one or more products or technologies which are themselves not aLicensed Product.

**1.10 “Commercially Reasonable Efforts**” means, with respect to either Party’s obligations under this Agreement, the carrying out of such obligationswith a level of efforts and resources consistent with the commercially reasonable practices of such Party for the active and diligent commercialization of a similarly situated branded pharmaceutical product as the Licensed Product at a similar stage of commercialization, taking into account efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors (but not taking in account any payment owed to Licensor under this Agreement or any other pharmaceutical product that the Company is then researching, developing or commercializing, alone or with one or more collaborators).

**1.11** **“Company”** has the meaning set forth in the Introductory Paragraph of the Agreement.

**1.12** **“Company Indemnitee”** shall have the meaning set forth in Section 13.1.

**1.13** **“Company Know-How”** shall have the meaning set forth in Section 4.3.2.

**1.14** **“Company Sole Inventions”** shall have the meaning set forth in Section 5.2.1.

**1.15 “Competent Authority”** means any applicable supranational, federal, national, regional, state or local regulatory agency, department, bureau,commission, council or other government entity with authority over the development, manufacture, use, marketing and/or sale (including approval of NDAs and other equivalent Marketing Authorization applications) of a pharmaceutical product in any regulatory jurisdiction in the Territory.

**1.16** **“Consent”** shall have the meaning set forth in Section 12.1.3.

**1.17 “Controlled”** means, with respect to particular information, materials or an intellectual property right, that the applicable Party owns or has alicense to such item and has the ability to grant to the other Party access to and a license or sublicense (as applicable) under such item as provided under this Agreement, without violating any obligation of such Party to a Third Party.

**1.18** **“Development”** means the Company’s, Affiliate’s, or Sublicensee’s use of Commercially Reasonable Efforts to:

1.18.1 secure the Marketing Authorizations for Licensed Product; and

1.18.2 manufacture the Licensed Product.

- 2 -



**1.19** **“Dispute”** shall have the meaning set forth in Section 9.1.1.

**1.20** **“FDA”** means the Food and Drug Administration in the United States and any successor entity thereto.

**1.21** **“Field of Use”** means all uses.

**1.22 “First Commercial Sale”** means with respect to any country in the Territory, the first sale of a Licensed Product in such country to a Third Partyby or on behalf of the Company, its Affiliates or Sublicensees after Governmental Approval has been obtained in such country.

**1.23 “Governmental Approval(s)”** means any and all permits, licenses and authorizations required by any Regulatory Authority as a prerequisite tothe development, manufacturing, packaging, marketing and/or selling of the Licensed Product in the Field of Use in the Territory, excluding import permits.

**1.24** **“Governmental Authorities”** shall have the meaning set forth in Section 12.1.2.

**1.25 “Improvements”** means any modification, enhancement, or improvement of the Licensed Product, IP Rights, or any inventions (whetherpatentable or not), information, data, or Patent Rights made by or on behalf of either Party at any time during the Term, including new indications.

**1.26 “IND(s)”** means an investigational new drug application as defined in 21 C.F.R. Section 312 et seq for the FDA in the United States or equivalentapplication to the Regulatory Authorities of other countries in the Territory, to commence clinical testing of a drug in humans, as defined by the FDA in the United States, or other applicable Regulatory Authority, as the same may be amended, supplemented or replaced from time to time.

**1.27 “Indication”** means a class of human disease or condition for which a separate NDA (including any extensions or supplements) is required to befiled with a Regulatory Authority. For clarity, if an NDA is approved for a Licensed Product in a particular Indication and patient population, a label expansion for such Licensed Product to include such Indication in a different patient population shall be considered a separate Indication.

**1.28 “Initial License”** means that certain exclusive license agreement that is between Tapestry Pharmaceuticals, Inc. (“Original Licensor”) and ArcherBiosciences, Inc. and that is effective as of April 2, 2008.

**1.29** **“IP Rights”** means the Patent Rights and the Know-How.

**1.30** **“Joint Invention”** shall have the meaning set forth in Section 5.2.2.

**1.31 “Know-How”** means all tangible or intangible information (other than those contained in the Patent Rights and other than Technical Data)whether patentable or not (but which has not been patented) that satisfies both (a) and (b) below: (a) is related to the Licensed Product or to an Improvement, including but not limited to: formulations, in vitro, preclinical or clinical design, information or results, trade secrets, other proprietary materials, processes, including but not limited to manufacturing processes, data, drawings and sketches, designs, testing and test results, regulatory information of a like nature, and (b) is Controlled by Licensor as of the Effective Date, or during the Term.

**1.32 “Licensed Product”** means products and/or formulations, including the methods of making product and/or formulation, containing the ActivePharmaceutical Ingredient, and, without limitation, intermediates, derivatives, analogues, or metabolites thereof, including, without limitation, oral and intravenous formulations, and any Improvements, all data, and information generated or related to such Licensed Product or within the scope one or more claims of the Patent Rights.

**1.33** **“Licensed Product Invention”** shall have the meaning set forth in Section 5.2.3.

- 3 -



**1.34** **“Licensor Indemnitee”** shall have the meaning set forth in Section 13.2.

**1.35** **“Licensor Sole Invention”** shall have the meaning set forth in Section 5.2.1.

**1.36** **“Loss”** shall have the meaning set forth in Section 13.2.

**1.37 “Marketing Authorization”** means all necessary regulatory approvals obtained by the Company or its permitted sublicensees, such as anapproved NDA, where applicable, to allow a Licensed Product to be marketed and sold in the Field of Use in a particular country or regulatory jurisdiction in the Territory.

**1.38** **“Milestone Event”** means any of the milestone events set out in Sections 6.3, 6.4, 6.5, 6.6, and 6.7.

**1.39** **“Milestone Payment”** means any of the milestone payments set out in Sections 6.3, 6.4, 6.5, 6.6, and 6.7.

**1.40 “NDA”** means a New Drug Application, and all amendments and supplements thereto, for regulatory approval by the FDA as defined in*21 CFR §**314.50* et seq., as such act or regulations may be amended, supplemented or replaced from time to time, to commence commercial sale of the LicensedProduct in the United States and any other comparable term and act as applicable with regard to a new drug application and all amendments, supplements or replacements to such act or regulations in any other country in the Territory.

**1.41** **“Net Sales”**

1.41.1 means the total gross amounts invoiced (or otherwise charged) for sales of Licensed Product by or on behalf of the Company or any of its Affiliates or any Sublicensees (as applicable), whether invoiced or not, to the first Third Party purchaser of a Licensed Product in an arms’ length transaction of the Licensed Product, less only the sum of the following:

1. tariff duties and/or use taxes directly imposed and with reference to particular sales;
2. amounts actually credited on returns of such Licensed Products actually sold;
3. outbound transportation prepaid and transportation insurance to the extent actually credited and properly documented; and
4. any royalties or similar payments made to Third Parties (other than royalty payments that reduce the royalties payable by the Company pursuant to Section 6.13).

1.41.2 Components of Net Sales shall be determined in the ordinary course of business using the accrual method of accounting in accordance with GAAP.

1.41.3 Notwithstanding anything herein to the contrary, the transfer of a Licensed Product to a Third Party without consideration to the Company in connection with the research, development or testing of a Licensed Product shall not be considered a sale of a Licensed Product under this Agreement. Nor shall the transfer of Licensed Product without consideration solely for indigent or similar public support or compassionate use programs be considered a sale of Licensed Product under this Agreement.

**1.42** **“Orphan Designation”** means the designation as defined in*21 CFR § 316*et seq, of a drug for a specified rare disease or condition.

- 4 -



**1.43** **“Patent Rights”** means the following, but solely to the extent such rights arise in the Territory.

1.43.1 all patents and patent applications set forth in Exhibit 1.43, in the Territory to the extent that the Licensor has rights under the Initial License;

1.43.2 any and all rights under patents and patent applications or other rights in the Territory owned or Controlled by the Licensor or that Licensor has or gains the ability to license, issuing from, or filed by Licensor subsequent to the Effective Date, which patents or applications contain claims covering any products, uses and/or formulations, including the methods of making product and/or formulation, which relate to the Active Pharmaceutical Ingredient, and, without limitation, intermediates, derivatives, analogues, or metabolites thereof, including, without limitation, oral and intravenous formulations. Such Patent Rights shall include, without limitation, any patents or patent applications owned or Controlled by the Licensor or that Licensor has or gains the ability to license based on or claiming priority to or from or containing Improvements to or covered by the applications and rights listed on Exhibit 1.43, including continuations, continuations in part, divisionals, reexaminations, extensions, and reissues from such applications and rights, and any patents resulting from any application or right included in Exhibit 1.43;

1.43.3 any other rights in any patents or patent applications owned or Controlled by the Licensor or that Licensor has or gains the ability to license to the Company relating to the Licensed Product as of the Effective Date and any and all patent applications, or other rights, including continuations, continuations in part, divisionals, reexaminations, extensions, and reissues that extend from such rights that are based on the foregoing patents and patent applications; and

1.43.4 any other intellectual property rights in any patents or patent applications owned or Controlled by the Licensor at any time during the Term of this Agreement relating to an Improvement or that Licensor has the ability to license or gains the ability to license to the Company as of the Effective Date relating to an Improvement; and any and all patents, patent applications, or other rights, including continuations, continuations in part, divisionals, reexaminations, extensions, and reissues extended from such rights.

Exhibit 1.43 shall be amended in writing from time to time, at the request of the Company, to reflect the foregoing.

**1.44 “Person”** means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, GovernmentalAuthority, association or entity.

**1.45 “Phase I Clinical Trial”** means a clinical trial whereby a pharmaceutical product is first introduced into humans in order to determine productsafety.

**1.46 “Phase II Clinical Trial”** means a clinical trial conducted to preliminarily evaluate the effectiveness of the pharmaceutical product for a particularindication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase II Clinical Trials are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. Phase II Clinical Trials will identify, among other things, the appropriate dose, dosage regimen, clinical endpoints, and statistical analysis parameters to be carried into Phase III Clinical Trials, in agreement with the applicable Competent Authority.

**1.47** **“Phase III Clinical Trial”** means a clinical trial that provides for expanded controlled and uncontrolled trials of pharmaceutical products. Phase

1. Clinical Trials are performed after preliminary evidence suggesting effectiveness of the pharmaceutical product has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the pharmaceutical product and to provide an adequate basis for physician labeling. Phase III Clinical Trials usually include from several hundred to several thousand subjects.
   * 5 -



**1.48 “Pivotal Trial”** means: (a) a Phase III Clinical Trial; or (b) any other human clinical trial that the applicable Regulatory Authority has agreed,whether before initiation of such clinical trial (e.g., pursuant to a special protocol assessment agreement with the FDA) or after first dosing of the first patient in such trial (e.g., based on an interim data analysis), is sufficient to form the primary basis of an efficacy claim in an application for Marketing Authorization, regardless of whether the sponsor of such trial characterizes or refers to such trial as a “Phase 3,” “Phase 2b” or “Phase 2b/3” trial (or otherwise) in the applicable protocol, on clinicaltrials.gov, or in any other context. If a human clinical trial does not constitute a Pivotal Trial at the time of initiation, but is later determined by the applicable Regulatory Authority to be sufficient to form the primary basis of an efficacy claim in an application for Marketing Authorization, then, for purposes of this Agreement, such clinical trial shall be deemed a Pivotal Trial on the date of such determination by the applicable Regulatory Authority.

**1.49 “Proof of Concept Study”** means a Phase II Clinical Trial that is appropriately designed to: (a) demonstrate efficacy in the disease to be studiedthrough relevant primary and/or secondary efficacy endpoints as described in a development plan for such trial; and (b) allow dose selection and support generation of efficacy data that would allow movement of the product into a Phase III Clinical Trial that would support seeking Governmental Approval in any country in the Territory.

**1.50** **“Regulatory Authority”** means the entities in a particular country or regulatory jurisdiction in the Territory responsible for:

1.50.1 the regulation of medicinal products intended for human use, including the FDA, the European Medicines Agency, the Ministry of Health, Labor and Welfare in Japan, and any other comparable, applicable administrative agency in any country in the Territory and any successor entities there; or

1.50.2 the establishment, maintenance, and/or protection of rights related to the Patent Rights and any other comparable, applicable administrative agency in any other country in the Territory and any successor entities thereto.

**1.51** **“Right of Reference”** shall have the meaning set forth in Section 4.3.1.

**1.52** **“Royalty Statement”** shall have the meaning set forth in Section 7.2.

**1.53 “Royalty Term”** means, with respect to a Licensed Product in a specific country in the Territory, the period commencing with the FirstCommercial Sale of such Licensed Product in the country in the Territory and ending upon the later of: (a) ten (10) years after such First Commercial Sale in such country; (b) expiration of regulatory or marketing exclusivity for such Licensed Product in such country; or (c) the expiration of the last to expire Valid Claim in such country covering such Licensed Product. After the end of a given Royalty Term in a given country, the Company will have an irrevocable, paid up, royalty-free license under the Patent Rights to make, have made, use, have used, import, offer to sell, sell and have sold Licensed Product in each such country, provided however, that any Valid Claim that has been pending more than five (5) years shall be deemed expired.

**1.54** **“Sole Invention”** shall have the meaning set forth in Section 5.2.1.

**1.55** **“Stock Purchase Agreement”** means that certain Stock Purchase Agreement, dated July 29, 2024, between the Parties.

**1.56 “Sublicensee”** means a Third Party that has entered into a license agreement with the Company sublicensing any of the rights granted underSection 2.1 or a Party that has entered into a license agreement with a Sublicensee sublicensing any of the rights granted under Section 2.1 (as applicable).

**1.57 “Technology”** means, without limitation, any information or data of the Licensor necessary or reasonably useful for Company to enable theCompany to undertake the manufacture, Development and commercialization of the Licensed Product in the Field of Use.

**1.58 “Technical Data”** means all technical, clinical, scientific, chemical, biological, pharmacological, validation, toxicological, research and test datagenerated with respect to the Licensed Product (including any data generated from any clinical trials), and all common law copyrights associated therewith, that are in existence as of the Effective Date.

- 6 -



**1.59** **“Term”** has the meaning set forth in Section 10.1.

**1.60** **“Territory”** means the United States, Canada, Mexico, and Japan.

**1.61** **“Third Party”** means any Person other than Company, Licensor and their respective Affiliates.

**1.62** **“Third Party Claim”** shall have the meaning set forth in Section 13.1.3.

**1.63** “**Trading Market**” means the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York StockExchange, or the NYSE American (or any successors to any of the foregoing).

**1.64 “Valid Claim”** means any pending or issued claim included within the Patent Rights that has not been permanently revoked, nor held to beunenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is no longer unappealable and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.

**Article 2**

**Grant**

**2.1** **Grant of License**.

2.1.1 Licensor hereby grants to the Company, and the Company accepts, subject to the terms and conditions of this Agreement, an exclusive license in the Territory:

1. to the IP Rights and Orphan Designation for the Licensed Product, if any;
2. to make, have made, use, import, export, offer for sale, sell, distribute and market the Licensed Products to the full end of the Royalty Term, unless sooner terminated as hereinafter provided; and
3. sublicense to Third Parties, in accordance with Section 2.3 below, any or all of the rights granted under this Section 2.1 in accordance with Section 2.3.

2.1.2 The license granted herein to Company shall also include the right to make or have made Licensed Products outside of the Territory, provided that the use or sale of such Licensed Products occurs solely within the Territory. Likewise, Licensor shall retain the right to grant a license to a Third Party under the IP Rights to make or have made products under the IP Rights within the Territory, provided that the use or sale of such products by such Third Party or Third Parties occurs solely outside of the Territory. Notwithstanding the above, except as provided in Section 2.1.2, Licensor shall not conduct activities related to the Licensed Product within the Territory.

**2.2 No Implied Licenses; Negative Covenant**. Except as expressly set forth in this Agreement, neither Party shall be deemed (by estoppel,implication, or otherwise) to have granted the other Party any license or other right to any intellectual property of such Party. The Company covenants that it will not, and will not permit any of its Affiliates or Sublicensees to, use or practice any IP Rights outside the scope of the license granted to it under Section 2.1.

**2.3** **Sublicenses**.

2.3.1 The Company shall not have the right to sublicense rights granted in Section 2.1 to its Affiliates and/or any Third Party, except with the prior written consent of Licensor (not to be unreasonably withheld) and subject to Section 2.3.3. At the time of the execution of a permitted sublicense agreement, the Company shall provide Licensor with a copy thereof.

- 7 -



2.3.2 Sublicensees that are Affiliates of the Company, or Third Party Sublicensees of the Company or its Affiliates, shall not have the right to grant further sublicenses, except with the prior written consent of Licensor (not to be unreasonably withheld) and subject to Section 2.3.3. At the time of the execution of a permitted sublicense agreement, such Affiliate Sublicensee or Third Party Sublicensee shall provide Licensor with a copy thereof.

2.3.3 In the event that Licensor consents to the grant of a sublicense by the Company or its Affiliate or any Third Party Sublicensee, then any agreement containing such permitted sublicense shall include the following: (a) an obligation for the recipient of such sublicense to account for and report its Net Sales on the same basis as if such sales were Net Sales by the Company; (b) that no action be taken that is inconsistent with the terms of this Agreement, including without limitation the prohibition of sales outside of the Territory; and (c) that Licensor shall be an intended third party beneficiary of such agreement, with the ability to enforce its rights or the rights of any permitted sublicensor. No sublicense agreement shall contain any provisions which are inconsistent with the terms of this Agreement, and all such sublicense agreements shall by their terms terminate upon termination of this Agreement, except as set forth in 2.3.4 below.

2.3.4 Upon termination of this Agreement, all sublicenses shall terminate; except that, any Sublicensee not in default of any of its material obligations pursuant to the sublicense that agrees in writing to be bound by all of the terms and conditions of this Agreement shall survive termination of this Agreement and be automatically and immediately assigned to Licensor on the condition that Licensor’s obligations to such Sublicensee shall not exceed the scope of Licensor’s obligations under this Agreement.

2.3.5 The terms of this Section 2.3 shall apply to each Sublicensee as if same were the Company’s original Sublicensee.

2.3.6 Limitations. Neither Company nor Licensor, nor any of their Sublicensees or direct licensees shall: (a) knowingly sell Licensed Product to any Person: (i) with respect to Company or its Sublicensees, outside the Territory; and (ii) with respect to Licensor or its licensees, in the Territory; or (b) knowingly sell Licensed Product to any Person that Company, Licensor or their respective Sublicensees or licensees has reason to know will sell Licensed Product in violation of subparagraph (a) above. Each Party and their respective Sublicensees or licensees shall immediately notify the other Party if it is aware of any violation of this Section 2.3.6 and cease providing to such Person any Licensed Product. The restrictions in Sections 2.3.1 and 2.3.2 related to the ability of the Company to sublicense rights granted in Section 2.1 to its Affiliates shall only apply to the extent the absence of such provisions would violate the Initial License, as in effect at the time of such determination, and such restrictions in Sections 2.3.1 and 2.3.2 will not apply if the Initial License is expired or terminated.

**Article 3**

**Technology Transfer**

**3.1 Technology Transfer**. Licensor shall provide the Company with all Know-How of the Licensor licensed to the Company, to the extent Licensorhas access to such information and on an “AS-IS” basis (the “Limitation”), to enable the Company to undertake the rights granted under this Agreement including, but not limited to, the manufacture, Development and commercialization of the Licensed Product(s) in the Field of Use under this Agreement. Subject to the Limitation, such Know-How shall include:

3.1.1 copies of all regulatory submissions of Licensor that cover Licensed Product;

3.1.2 any communications with the FDA and the minutes of any meetings with the FDA relating to the Licensed Product;

3.1.3 data, studies, results and reports resulting from pre-clinical studies, including in vivo and in vitro studies, in Licensor’s possession, custody or control on Licensed Product;

- 8 -



3.1.4 trial master files relating to the Licensed Product, including copies of all related case report forms;

3.1.5 copies of all listings and tables of results from the clinical trials of the Licensed Product;

3.1.6 copies of all treatment-related serious adverse event reports from the clinical trials of the Licensed Product;

3.1.7 storage of and access permission to any retained samples of materials used in clinical trials of the Licensed Product;

3.1.8 access to contract research organizations (“**CROs**”) involved in the clinical trials clinical of the Licensed Product;

3.1.9 the data and results of any chemistry, manufacturing, and controls (“**CMC**”) related activities regarding the Licensed Product;

3.1.10 all other information that the Company may reasonably request regarding relevant documentation covering the use and manufacture of the Licensed Product by Licensor; and

3.1.11 Licensor shall provide the Company with reasonable technical assistance from personnel employed by Licensor related to the manufacture and use of the Licensed Product, including documentation related to the use and manufacture of the Licensed Product.

**3.2** **Transfer, Assignment and Sale of Compound Inventory and Costs of Transfer**.

3.2.1 Unless otherwise prohibited by law, Licensor hereby, effective as of the Effective Date, assigns, sells and transfers to the Company all Licensor’s right, title and interest in and to current inventory of drug supply and bulk material, as set forth on Exhibit 3.2 (“**Existing Inventory**”). Promptly following the Effective Date, if and as instructed to do so in writing by the Company not more than sixty (60) days thereafter, Licensor shall make available and transfer to the Company the Existing Inventory, at the Company’s sole expense, pursuant to Section 3.2.2.

3.2.2 The Company shall pay to Licensor all of Licensor’s actual internal and external out-of-pocket costs of providing the information and services described in Section 3.1, not to exceed ten thousand dollars ($10,000) in the aggregate.

**Article 4**

**Regulatory Compliance**

**4.1** **Ownership and Maintenance of Governmental Approvals**.

4.1.1 The Company will own all Marketing Authorizations for each country in the Territory for Licensed Product. Without limiting the generality of the foregoing, the Company shall prepare and submit in its own name and at its expense NDAs with the FDA in the U.S. and any other equivalent application with the Regulatory Authorities in other countries in the Territory.

4.1.2 The Company shall secure and maintain in good standing, at its sole cost and expense, any and all Governmental Approvals (including Marketing Authorizations, licenses, facility licenses and permits required by Applicable Laws or by the applicable Regulatory Authorities) necessary and/or required for the Company to perform its obligations under this Agreement and use Commercially Reasonable Efforts, at its sole cost and expense, to secure and maintain any required variations and renewals thereof.

- 9 -



**4.2 Pharmacovigilance.** The Company shall be solely responsible, at its sole cost and expense, for following the guidelines and procedures for thereceipt, investigation, recording, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, and any other information concerning the safety of the Licensed Product, and other routine pharmacovigilance reporting requirements, in the Territory. Such guidelines and procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws. The Company shall cause its Affiliates and permitted Sublicensees to comply with such obligations.

**4.3** **Rights of Reference**.

4.3.1 Licensor shall grant and hereby grants the Company and its Sublicensees a right to reference, use, and have full access to all existing Governmental Approvals and all other regulatory documents relating to Licensed Product in the possession and Control of Licensor relating to Licensed Products, including any IND, any NDA and any Drug Master File (“**DMF**”) (whether as an independent document or as part of any NDA, and all chemistry, manufacturing and controls information) covering the Licensed Product, and any supplements, amendments or updates to the foregoing, where such regulatory documents are Controlled by Licensor or its licensees, for the purpose of the Company’s Development and seeking Marketing Authorizations for Licensed Product in the Field of Use (the “**Right of Reference**”). The Rights of Reference provided shall be used solely within the Territory. Subject to the limitations set forth in this Agreement, the Company may license the Right of Reference to Affiliates and to Sublicensees.

4.3.2 The Company will provide Licensor (or Licensor’s successor in interest) with all data (including pre-clinical, clinical, and other data) (the “**Company Know-How**”) relating to Licensed Product for use in obtaining and maintaining registrations or Governmental Approvals outside the Territory by Licensor or its licensees. The Company will provide Licensor and its licensees rights of reference (as included in this Section 4.3) and access to regulatory filings and approvals for use outside the Territory. Any licenses entered into by Licensor shall have reciprocal obligations imposed upon licensees.

**4.4 Access to Manufacturers**. Licensor agrees to disclose to the Company the names of any of its suppliers of the API of the Licensed Product, thefinished drug product, and all related drug material and to permit the Company to deal directly with such suppliers (if any) in seeking supply of the API.

**4.5** **Transfer of the IND**.

4.5.1 The Parties acknowledge that Licensor, as of the Effective Date, owns and holds certain Governmental Approvals and/or INDs in connection with the research and development of the Licensed Product. Promptly after the Effective Date, Licensor shall: (a) assign and transfer to the Company, without any additional consideration, all such Governmental Approvals and/or INDs relating to the Licensed Product in the Territory; and (b) execute a letter notifying the FDA, and any other applicable Regulatory Authority, of the transfer of such INDs to the Company.

4.5.2 During the time that Licensor is the holder of the Governmental Approvals and/or IND, the Company shall be entitled to attend any and all meetings and participate in telephone calls with the Regulatory Authorities relating to Licensor’s development of Licensed Product, including without limitation any meeting preparation, meeting co-ordination, preparation of minutes, and pre-NDA meeting with the FDA covering Licensed Product in the Territory.

- 10 -



**Article 5**

**Development and Commercialization**

**5.1 Development & Commercialization**5.1.1. The Company shall use Commercially Reasonable Efforts, and shall cause its sublicensed Affiliatesand its Sublicensees to use Commercially Reasonable Efforts, to perform the Development and commercialization of Licensed Products for an oncology indication in the Territory. Such Development efforts will include, but may not be limited to the prosecution and maintenance of existing and new intellectual property; preclinical and clinical development of the Licensed Products including research, manufacturing, laboratory and clinical testing, regulatory filing, and marketing of the Licensed Products in the Territory. The Company shall provide Licensor with quarterly updates and detailed, semi-annual written Development updates summarizing the Company’s progress and goals for the Development and commercialization of Licensed Products. If this last sentence of Section 5.1 does not conflict with the terms of the Initial License in effect on the date of any determination of the satisfaction of Commercially Reasonable Efforts (or if the Initial License is expired or terminated as of the date of such determination of the satisfaction of Commercially Reasonable Efforts), and if: (a) the Company successfully completes any of the milestones set forth in Section 6.7; and (b) the Licensor receives the corresponding milestone payment for such milestone (and the Licensor has previously received the milestone payments for each of the prior milestones), then the Company shall be deemed to have satisfied the Commercially Reasonable Efforts requirements in this Section 5.1 for the period from the Effective Date through the date of Licensor’s receipt of such corresponding milestone payment.

**5.2** **Ownership of Inventions**.

5.2.1 **Sole Inventions**. Subject to Section 2.1, each Party shall exclusively own all inventions conceived solely by such Party, itsemployees, agents and consultants made in the course of Development of the Licensed Product hereunder (the “**Sole** **Inventions**”). The Company shall exclusively own Sole Inventions conceived solely by the Company, its employees, agents andconsultants (the “**Company Sole Inventions**”). The Licensor shall exclusively own Sole Inventions conceived solely by Licensor, its employees, agents and consultants (the “**Licensor Sole Inventions**”).

5.2.2 **Joint Inventions**. Subject to Section 2.1, the Parties shall jointly own all inventions conceived jointly by employees, agents andconsultants of the Company and Licensor, which are conceived in the course of Development of a Licensed Product hereunder, on the basis of each Party having an undivided interest in the whole (the “**Joint Invention**”).

5.2.3 **Patentable Inventions**. Notwithstanding Sections 5.2.1 and 5.2.2, in the event a Licensor Sole Invention or a Joint Invention isa discovery, invention, Improvement, or new use of the Licensed Product (a “**Licensed Product Invention**”), then Exhibit 1.43 shall be amended and updated to include such Licensed Product Inventions and such Licensed Product Inventions shall be deemed Patent Rights.

5.2.4 **License to Licensor**. Subject to the terms and conditions of this Agreement, the Company hereby grants to Licensor, outside theTerritory, a fully paid up, royalty-free, perpetual, irrevocable, non-exclusive license to any Company Sole Invention (and intellectual property rights related to such Company Sole Invention) for any purpose.

5.2.5 **Inventorship**. For purposes of determining whether an invention is a Company Sole Invention, Licensor Sole Invention, or JointInvention, questions of inventorship shall be resolved in accordance with United States patent laws.

5.2.6 **Termination Provisions**. Sections 5.2.3 and 5.2.4 shall automatically be deleted from this Agreement on the first date that either

1. the removal of such provisions would no longer violate the Initial License; or (b) the Initial License expires or terminates.
   * 11 -



**Article 6**

**Royalties, Milestones, and Other Consideration**

**6.1 Obligation to Pay**. The Company agrees to pay (and shall ensure that all of its Affiliates, and all Sublicensees, pay) to Licensor the payments setforth below, and in accordance with the provisions hereof, to the end of the Term or until this Agreement shall be terminated as hereinafter provided.

**6.2 Execution Payment**. The Company shall pay Licensor up to six hundred sixteen thousand six hundred ninety-eight (616,698) shares of theCompany’s common stock subject to, and in accordance with, the terms of the Stock Purchase Agreement.

**6.3 Milestone for Licensed Products**. The Company shall pay (in cash) Licensor the following non-creditable, non-refundable, one time MilestonePayments upon achievement (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) of the applicable Milestone Events for a CNS Indication for any Licensed Product. The Company will promptly notify the Licensor of achievement of each Milestone Event described below.

6.3.1 $250,000 payment upon the dosing of the first patient in a Phase I Clinical Trial for a CNS Indication.

6.3.2 $250,000 payment upon the dosing of the first patient in a Phase II Clinical Trial for a CNS Indication.

6.3.3 $1,000,000 payment upon the dosing of the first patient in a Phase III Clinical Trial for a CNS Indication.

6.3.4 $5,000,000 payment upon approval of an NDA in the United States by the FDA for a CNS Indication.

**6.4 Development Based Milestone and Other Payments for Intravenous Formulation.** The Company shall pay (in cash) Licensor the followingnon-creditable, non-refundable, one time Milestone Payments upon achievement (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) of the applicable Milestone Events for an intravenous formulation of the Licensed Product. The Company will promptly notify the Licensor of achievement of each Milestone Event described below.

6.4.1 $1,000,000 USD upon acceptance for filing of an NDA in the US by the FDA;

6.4.2 $3,000,000 USD upon approval of an NDA in the US by the FDA;

6.4.3 $1,000,000 USD upon approval of a Marketing Authorization in Japan by the Ministry of Health, Labor, and Welfare.

**6.5 Development Based Milestone and Other Payments for Oral Formulation**. The Company shall pay (in cash) Licensor the following non-creditable, non-refundable, one time Milestone Payments upon achievement (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) of the applicable Milestone Events for an oral formulation of the Licensed Product. The Company will promptly notify the Licensor of achievement of each Milestone Event described below.

6.5.1 $250,000 USD payable upon the dosing of the first patient in an oral formulation Company-sponsored Clinical Trial (either a Phase I Clinical Trial or a Phase II Clinical Trial);

6.5.2 $1,000,000 USD payable upon the dosing of the first patient in an oral formulation Company-sponsored Phase III Clinical Trial;

6.5.3 $3,000,000 USD upon acceptance for filing of an NDA in the US by the FDA;

- 12 -



6.5.4 $5,000,000 USD upon approval of an NDA in the US by the FDA; and

6.5.5 $2,000,000 USD upon approval of a Marketing Authorization in Japan by the Ministry of Health, Labor, and Welfare.

**6.6 Sales Milestones**. During the Royalty Term, the Company shall pay (in cash) Licensor non-creditable, non-refundable Milestone Payments of$2,000,000 USD for every $100,000,000 USD in cumulative Net Sales (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) regardless and irrespective of formulation or Indication.

**6.7 Additional Milestones.** In addition to the milestone payments described in Sections 6.3 – 6.6, the Company shall also pay Licensor the followingnon-creditable, non-refundable Milestone Payments upon achievement (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) of the applicable Milestone Events for the first Indication of any Licensed Product. If any Licensed Product achieves (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) any Milestone Events for a second Indication in another therapeutic category (e.g., central nervous system disorder versus an oncology indication), then the Company will, in addition to the amounts specified below, pay to the Licensor a second Milestone Payment equal to fifty percent (50%) of the Milestone Payment amount listed below. The Company will promptly notify the Licensor of achievement of each Milestone Event described below, and Licensor, in its sole discretion, will notify the Company of Licensor’s election to receive the Milestone Payment in cash or equity for each such Milestone Event, with any such issuance of equity to be subject to, and in accordance with, the terms of the Stock Purchase Agreement and, in each case, with the specific number, class and issuer of shares in the table below to be appropriately and equitably adjusted to reflect any stock split or combination, dividend, reorganization, reclassification, recapitalization, merger, business combination, exchange or readjustment of shares or other similar event. The Licensor’s ability to receive any Milestone Payments in equity shall be subject to the approval by the Company’s shareholders of the NASDAQ Proposal (as defined in the Stock Purchase Agreement). To the extent the Licensor elects to receive a cash payment, the Company shall have a period of three (3) months from the notice of such election to make fifty percent (50%) of such cash payment and six

(6) months from the notice of such election to make fifty percent (50%) of such cash payment.

|  |  |  |
| --- | --- | --- |
| **Milestone Event** |  | **Milestone Payment** |
|  | **Cash Payment Option** | **Equity Payment Election** |
| Meeting the primary endpoint of the Pivotal Trial for a | $15,000,000 | Four hundred eleven thousand one hundred thirty-two (411,132) |
| Licensed Product |  | shares of the common stock of the Company not to exceed a value of |
|  |  | $30,000,000 |
| FDA acceptance of an NDA for a Licensed Product | $30,000,000 | Eight hundred twenty-two thousand two hundred sixty-four |
|  |  | (822,264) shares of the common stock of the Company not to exceed |
|  |  | a value of $70,000,000 |
| The First Commercial Sale in the United States of a | $45,000,000 | One million two hundred thirty-three thousand three hundred ninety- |
| Licensed Product |  | five (1,233,395) shares of the common stock of the Company not to |
|  |  | exceed a value of $90,000,000 |
| The First Commercial Sale in Japan of a Licensed | $10,000,000 | Two hundred five thousand five hundred sixty-six (205,566) shares |
| Product |  | of the common stock of the Company not to exceed a value of |
|  |  | $20,000,0000 |

“Value” of Company common stock shall mean, for any date, the price determined by the first of the following clauses that applies: (a) if the Company common stock is then listed or quoted on a Trading Market, the average closing price of the Company common stock during the ten trading days ending on the date in question (or the nearest preceding date if such date is a day on which the Trading Market is closed) on the Trading Market on which the Company common stock is then listed or quoted, (b) if the Company common stock is not then listed or quoted for trading on a Trading Market and if prices for the Company common stock are then reported on the OTCQB or OTCQX or the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the average of the closing bid price of the Company common stock so reported during the ten trading days ending on the date in question, or (c) in all other cases, the fair market value of the Company common stock as determined by an independent appraiser selected in good faith by the Company and reasonably acceptable to the Seller Representative, the fees and expenses of which shall be paid by the Company.

- 13 -



**6.8 Royalties on Net Sales.** Subject to Section 6.13, within thirty (30) days following the end of each calendar quarter during the Royalty Term for agiven Licensed Product, the Company shall pay (in cash) to Licensor non-creditable, non-refundable royalties on Net Sales (by or on behalf of the Company, or any of its Affiliates, or any Sublicensees, as applicable) of such Licensed Product in the Territory during such calendar quarter, as calculated by multiplying the applicable royalty rate by the corresponding amount of cumulative Net Sales in the Territory, as follows:

|  |  |  |
| --- | --- | --- |
| **Cumulative Net Sales Threshold** | **Royalty Rate** |  |
| Net Sales of all Licensed Products in Canada and Mexico during the Royalty | 3.0% |  |
| Terms for such Licensed Products. |  |
|  |  |
| Less than or equal to $500,000,000 in cumulative Net Sales of all Licensed |  |  |
| Products in the United States and Japan during the Royalty Terms for such | 6.0% |  |
| Licensed Products. |  |  |
| Greater than $500,000,000 in cumulative Net Sales of all Licensed Products |  |  |
| in the United States and Japan during the Royalty Terms for such Licensed | 7.5% |  |
| Products. |  |  |

**6.9 No Multiple Royalties**. No multiple royalties shall be payable because the use, lease or sale of any Licensed Product is, or shall be, covered bymore than one Valid Claim contained in the Patent Rights.

**6.10** **Product Bundling and Combination**.

6.10.1 Bundling. No reduction in price for Licensed Products as a result of “product bundling” shall be recognized under the terms of this Agreement. In the event that a Licensed Product is sold at a reduced price in connection with a sale of a product which is not a Licensed Product, then the price for such Licensed Product for purposes of calculation of royalties shall be the full price customarily charged for such Licensed Product in a stand-alone, arms’ length transaction.

6.10.2 Combination. In the event that the Licensed Product is sold as part of a Combination Product, the Net Sales of the Licensed Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the Combination Product by the fraction A/(A+B), where A is the weighted (by sales volume) average sale price of Licensed Product when sold separately in finished form and B is the weighted average sale price of the other product(s) sold separately in finished form in such country. In the event that such average sale price cannot be determined for both Licensed Product and the other product(s) in combination, Net Sales for purposes of determining royalty payments shall be mutually agreed by the Parties within a reasonable period of time prior to the first regulatory approval of such Combination Product based on all relevant factors including relative cost and the relative value contributed by each component, and such agreement shall not be unreasonably withheld. In no event shall the Net Sales price for a Licensed Product be reduced due to its inclusion in a Combination Product, compared to the weighted average sales price of such Licensed Product when sold separately in such country.

**6.11 Place of Payment, Taxes and Conversions**. Cash payments shall be paid by wire transfer in United States dollars at such place as Licensor mayreasonably designate consistent with Applicable Laws and regulations, and payments in stock will be paid through mutually agreeable stock purchase agreements. Any taxes which the Company, its Affiliate, or Sublicensee shall be required by law to withhold on behalf of Licensor on remittance of the payments to Licensor may be deducted from such payment to Licensor. The Company shall furnish Licensor with the original copies of all official receipts for such taxes, or other evidence of such withholding sufficient to enable Licensor to claim such payment of taxes from any applicable Governmental Authority, in a timely manner. The Company shall provide Licensor any tax forms or other similar documentation that may be reasonably necessary in order for Licensor not to make any tax withholdings or to make tax withholdings at a reduced rate under an applicable bilateral income tax treaty, and shall update such forms and documentation from time to time as necessary to reflect changes in facts. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of tax withholdings, value added tax (“**VAT**”) or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT. If any currency conversion shall be required in connection with the payments hereunder, such conversion shall be made by using the exchange rate prevailing at Citibank, N.A. in New York, New York on the last business day of the calendar quarterly reporting period to which such payments relate less any applicable fees associated with such exchange.

- 14 -



**6.12 Time for Payment; Interest**. Except as set forth in Section 6.7 with respect to the cash payments required thereunder, Milestone Paymentspayable to Licensor are due and payable within thirty (30) days after the achievement of the Milestone Event, except that the Milestone Payment set forth in Section 6.5.1 shall be payable within ten (10) days after achievement of the Milestone Event. If Licensor does not receive payment of any sum due to it on or before the due date, interest shall thereafter accrue on the sum due to Licensor until the date of payment at the per annum rate of five percent (5%) over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by Applicable Laws, whichever is lower, with such interest compounded quarterly.

**6.13** **Royalty Reduction for Infringement**. To the extent that:

1. the Company or any Affiliate of the Company is required by order or judgment of any court in any jurisdiction to obtain a license from a Third Party in any jurisdiction relating to the manufacture or composition of Licensed Product, in the Field of Use in the Territory; or
2. the Company or any Affiliate of the Company, in their reasonable discretion after appropriate legal analysis, believes it necessary to obtain a license from a Third Party in any jurisdiction relating to the manufacture or composition of Licensed Product, in the Field of Use in the Territory;

in order to sell a Licensed Product in such jurisdiction, then up to fifty percent (50%) of the reasonable royalties payable under such license in such jurisdiction may be deducted from royalties otherwise payable to Licensor hereunder in respect of such sales, provided that:

1. in no event shall the aggregate royalties payable to Licensor in any period in such jurisdiction be reduced by more than fifty percent (50%) as a result of any such deduction;
2. any excess deduction remaining as a result of such limitation may be carried forward to subsequent periods; and
3. no deduction shall be made for any judgment, license, or other obligation unless such obligation relates to Third Party intellectual property which claims the Active Pharmaceutical Ingredient, its use in the field of cancer, the formulations of the Active Pharmaceutical Ingredient in clinical trials as of the Effective Date, or claims the manufacturing methods which are used by Licensor to manufacture the Active Pharmaceutical Ingredient as of the Effective Date.

**6.14 Payment Requirements.** The Company shall have no obligation to make any of the payments set forth in Sections 6.3-6.6 to the extent theLicensor is not required to remit such payment(s) to the Original Licensor.

**Article 7**

**Reports and Records**

**7.1 Records and Audits**. The Company shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of accountcontaining all particulars that may be necessary for the purpose of showing the amounts payable to Licensor under this Agreement. Said books of account shall be kept at the applicable Party’s principal place of business, and such books and all the supporting data shall be made available once per year upon reasonable notice to the Company for inspection by Licensor’s internal audit division or by another designated auditor selected by Licensor, except one to whom the Company has reasonable objection, for the purpose of verifying the Company’s Royalty Statements and other payments and/or compliance in other respects with this Agreement. If any such inspection shows an under reporting or underpayment of amounts owed to Licensor, the Company shall make such needed payment within thirty (30) days of the inspection report including any late charges as required by Section 6.12 of this Agreement. In the event that such an audit shows an underreporting or underpayment of greater than five percent (5%), then the out of pocket costs of such audit shall be paid by the Company. Said books of account and the supporting data shall be made available to Licensor for one (1) year following expiry of the Term. All payments required under this Section 7.1 shall be due within thirty (30) days of the date Licensor provides the Company notice of the payment due.

- 15 -



**7.2 Royalty Statements**. Within thirty (30) days from the end of each calendar quarter of each calendar year, the Company shall deliver to Licensorcomplete and accurate reports, giving such particulars of the business conducted by the Company during the preceding quarter under this Agreement as shall be pertinent to an accounting of royalties and other payments that may be due to Licensor under this Agreement (each, a “**Royalty Statement**”). Each Royalty Statement shall include at least the following for the applicable quarter:

1. an accounting of all Licensed Product used or sold;
2. total amounts invoiced (or otherwise charged) for Licensed Product, on a country-by-country basis;
3. Net Sales for each Licensed Product by each of the Company, each Affiliate and each Sublicensee, on a country-by-country basis;
4. cumulative Net Sales for the current calendar quarter;
5. a breakdown of deductions applicable in computed Net Sales and taxes withheld, if any;
6. a breakdown of royalties due based on Net Sales by or for the Company and its Affiliates and Sublicensees, each listed separately;
7. a breakdown of royalties due from any Sublicensee;
8. names and addresses of all Sublicensees and Affiliates of the Company; and
9. a copy of each report from each Sublicensee as may be pertinent to an accounting of royalties and other payments that may be due to Licensor.

**7.3 Confidential Treatment of Reports**. Licensor agrees to hold in confidence each Royalty Statement delivered by the Company pursuant to thisArticle 7 until the termination of this Agreement. Notwithstanding the foregoing, Licensor may disclose any such information required to be disclosed in its financial statements or as required by any stock exchange or similar regulatory authority, or pursuant to any Applicable Laws, provided that Licensor takes reasonable steps to provide the Company with the opportunity, where appropriate, to contest such subpoena, requirement or order and may disclose the Royalty Statements as needed to enforce its rights under this Agreement.

**Article 8**

**Patent Prosecution and Maintenance**

**8.1 Prosecution and Maintenance**. Following the Effective Date, and subject to Section 8.1.1, the Company shall diligently prosecute and maintainthe Patent Rights in the Territory as set forth in Exhibit 1.43 hereto, (as may be amended, or supplemented, in writing from time to time after the Effective Date), including, but not limited to, the filing of patent applications, extensions, continuations, continuations-in-part, divisionals, re-examinations, or re-issue applications that the Company determines may be required to advance the purposes of this Agreement or otherwise to protect the rights and licenses granted hereunder. The Company agrees to keep Licensor well informed with respect to the status and progress of any such applications (including any new applications), prosecution and maintenance activities, and to consult in good faith with Licensor and take into account Licensor’s comments and requests with respect thereto prior to the filing of any such documents. Both Parties agree to provide reasonable cooperation to each other to facilitate the application and prosecution of patents pursuant to this Agreement.

- 16 -



8.1.1 Subject to Section 5.2, to the extent Licensor or any Affiliate or licensee of Licensor intends to file any additional patent application(s) directly or indirectly related to the Technology, Licensor will provide to the Company written notice of its intent to file the additional patent application(s) outside the Territory at least thirty (30) days before actual filing. Subject to Section 8.1, at the Company’s request, Licensor or any Affiliate or licensee of Licensor shall also concurrently file the additional patent application(s) in the Territory. Prior to filing such patent application(s) in the Territory, Licensor or any Affiliate or licensee of Licensor agrees to consult in good faith with Company and take into account any comments and requests that Company may have with respect to such patent application(s). Licensor also agrees to update Exhibit 1.43 to include the additional patent application(s) as Patent Rights. Within thirty (30) days of filing, the Company shall reimburse Licensor for any fees and costs associated with filing any additional patent application(s) in the Territory. Licensor’s obligation to provide notice under this section ends upon the first filing of any outside-the-Territory version of an NDA by Licensor.

8.1.2 Subject to Section 5.2, to the extent the Company intends to file any additional patent application(s) directly or indirectly related to the Technology, the Company will provide to Licensor written notice of its intent to file the additional patent application(s) inside the Territory at least thirty (30) days before actual filing. At Licensor’s request, the Company shall also file the additional patent application(s) outside the Territory. Within thirty (30) days of filing, Licensor shall reimburse the Company for any fees and costs associated with the filing of any additional patent application(s) outside the Territory. At its option, the Company shall, or by written notice shall permit Licensor to, diligently prosecute and maintain the additional patent application(s) outside the Territory at Licensor’s sole expense. The Party prosecuting the patents shall keep the other Party reasonably well informed with respect to the status and progress of any such additional patent application(s), prosecution and maintenance activities, and to consult in good faith with the non-prosecuting Party and take into account the non-prosecuting Party’s comments and requests with respect thereto. The Company’s obligation under this section ends upon the first filing of an NDA by the Company in the United States.

8.1.3 As of the Effective Date, the Company shall assume all outstanding amounts due to Licensor’s intellectual property counsel for the prosecution and maintenance of the Patent Rights prior to the Effective Date in an amount not to exceed $580,000.

8.1.4 Sections 8.1.1 and 8.1.2 shall automatically be deleted from this Agreement on the first date that either: (a) the removal of such provisions would no longer violate the Initial License; or (b) the Initial License expires or terminates.

**8.2 Abandonment**. The Company may, in its discretion, elect to abandon any patent applications or issued patent in the Patent Rights. Following adecision by the Company to abandon a patent application or issued patent, Licensor shall have the right, but not the obligation, to commence or continue such prosecution and to maintain any such Patent Rights under its own control and at its own expense. Prior to any such abandonment, the Company shall give Licensor at least sixty (60) days’ notice and a reasonable opportunity to take over prosecution and maintenance of such Patent Rights. The Company agrees to cooperate in such activities including execution of any documents necessary to enable Licensor to prosecute such Patent Rights. In the event Licensor elects to commence or continue such prosecution of the Patent Rights after the Company’s decision to abandon, the Company hereby assigns all of its right, title, and interest in and to such abandoned Patent Right to Licensor.

**Article 9**

**Dispute Resolution**

**9.1** **Disputes**.

9.1.1 The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to either Party’s rights and/or obligations hereunder or to the interpretation, performance, breach, or termination of this Agreement (a “**Dispute**”). It is the objective of the Parties to establish procedures to facilitate the resolution of a Dispute in an expedient and effective manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 9 if and when a Dispute arises under this Agreement.

- 17 -



9.1.2 A Dispute among the Parties that arises shall be promptly presented (by either Party) to the Chief Executive Officers of Licensor and the Company, or their respective designees (who must be members of the applicable Party’s senior management) for resolution, and such individuals shall discuss the Dispute and seek to agree on a resolution of the Dispute promptly and in good faith. From the date of referral of a Dispute to the Chief Executive Officers or their designees of the Parties and until such time as any matter has been resolved by the Parties or has been finally settled by arbitration hereunder, the running of the cure periods (if any) as to which a Party must cure a breach that is part of the subject matter of any Dispute shall be suspended (so long as such Party is participating in good faith in the process to resolve such Dispute). In the event that the Chief Executive Officers of Licensor and the Company, or their respective designees, cannot after good faith negotiations resolve the Dispute within thirty

1. days (or such other period of time as mutually agreed to by the Parties in writing) of being requested by a Party to resolve a Dispute, the Parties agree that such Dispute shall be resolved by binding arbitration in accordance with this Section 9.1.

9.1.3 If a Party intends to begin arbitration to resolve such Dispute as provided above, such Party shall provide written notice (the “**Arbitration Notice**”) to the other Party informing such other Party of such intention and the issues to be resolved. Any arbitration hereunder shall be conducted pursuant to the Commercial Arbitration Rules of the American Arbitration Association (“**AAA**”), including the Supplementary Procedures for Large Complex Disputes (the “**AAA Rule**”) except as modified herein. The arbitration shall be conducted by a panel of three (3) neutral, independent arbitrators (the “**Panel**”) to be mutually agreed upon by the Parties and appointed by the AAA. The arbitrators shall be industry experts experienced in the issues comprising the Dispute and shall have no past, present or anticipated future affiliation with either Party. If the Parties are unable to agree upon all or any number of the three (3) mutually acceptable arbitrators within thirty (30) days after the filing of the Arbitration Notice, the AAA shall promptly appoint the arbitrator(s) to complete the Panel in accordance with the criteria set forth in this Section 9.1.3. The arbitration shall take place in New York, NY, or such other location mutually agreed upon by the Parties. The Panel shall apply the governing law in Section 16.9. The Panel shall issue appropriate protective orders to protect each Party’s Confidential Information. If a Party can demonstrate to the Panel that the complexity of the issue or other reasons warrant the extension of one or more timetables in the AAA Rules, the Panel may extend such timetables but in no event shall the proceeding extend more than twelve (12) months from the date of filing of the Arbitration Notice with the AAA. The Panel’s decision shall be in writing. Except for any dispute arising in connection with Section 2.2, the Panel shall have the authority to award any remedy allowed by law or in equity, including compensatory damages, pre judgment interest and to grant final, complete, interim, or interlocutory relief, including specific performance, injunctions and other equitable relief, but shall not have any authority to award indirect, incidental, special, consequential, punitive or other damages, and each Party shall be deemed to have waived any right to such excluded damages. Each Party shall bear its own costs, fees and expenses in the arbitration and shall share equally the Panel’s fees, except as otherwise provided by the Panel.

**9.2 Performance to Continue**. Each Party shall continue to perform its obligations under this Agreement pending final resolution of any Disputearising out of or related to this Agreement; provided, however, that a Party may suspend performance of its obligations during any period in which the other Party fails or refuses to perform its obligations.

**9.3 Determination of Patents and Other Intellectual Property**. Notwithstanding the foregoing, any dispute relating to the determination of validityof claims, infringement or claim interpretation relating to Licensor’s Patent Rights shall be submitted exclusively to the courts having jurisdiction over the applicable patents.

**9.4 Statute of Limitation and Time-Based Defenses Tolled**. All applicable statutes of limitation and time-based defenses (such as estoppel andlaches) shall be tolled while any arbitration proceedings are pending and during any arbitration proceedings under Section 9.1, so long as the Party subject to such statutes, or asserting such defenses, is participating in good faith in such proceedings. The Parties shall cooperate in taking any actions necessary to achieve this result.

- 18 -



**Article 10**

**Term and Termination**

**10.1 Term**. This Agreement shall become effective on the Effective Date and shall expire on the date of the expiration of the last to expire RoyaltyTerm for the last Licensed Product in any country in the Territory (the “**Term**”), unless earlier terminated as provided in Sections 10.2, 10.3, or 10.4.

**10.2 Termination for Material Breach**. Upon any material breach or default of this Agreement by a Party, the non-breaching Party shall have the rightto terminate this Agreement and the rights, privileges, and license granted hereunder by giving one hundred eighty (180) days prior written notice to the breaching Party. Upon the expiration of the one hundred eighty (180) day period, if the breaching Party has not cured such breach or default, this Agreement shall, at the option of the non-breaching Party, terminate upon written notice to the breaching Party. In the event of a bona fide Dispute between the Parties over whether any material breach has occurred, the Parties shall attempt to resolve such Dispute in accordance with Section 9.1 as soon as possible, and this Agreement shall not terminate during such Dispute resolution process, and as such this license shall remain in full force and effect until such Dispute is settled or otherwise resolved under Section 9.1. In the event that the Company files for bankruptcy, Licensor may terminate this Agreement upon ten (10) days written notice to the Company.

**10.3 Expiry of Royalty Term on a Country by Country Basis**. Upon expiry of the Royalty Term in each country in the Territory, the Company willhave an irrevocable, paid up, royalty-free license under the IP Rights to make, have made, use, import, offer for sale, distribute, and sell such Licensed Product in such country.

**10.4 Termination for Convenience**. The Company shall have the right at any time to terminate this Agreement, partial with respect to any jurisdictionwithin the Territory, or in its entirety, for any reason or no reason, by giving ninety (90) days’ notice thereof in writing to Licensor.

**10.5** **Consequences of Termination**.

10.5.1 Upon the early termination of this Agreement by Licensor, or the Company, under Section 10.2 or by Company under Section

10.4, the following shall occur:

1. Subject to Section 10.5.1(c), the Company shall have no right to practice within the IP Rights or use any of the IP Rights, and all rights, title or interest in, or other incidents of ownership under the IP Rights shall revert to and become the sole property of Licensor, provided that survival of sublicenses granted shall be governed by Section 2.3.4;
2. The Company shall promptly assign (at the Company’s expense) to Licensor: (i) all Governmental Approvals (including Marketing Authorizations, licenses, facility licenses and permits required by Applicable Laws or by the applicable Regulatory Authorities) for the Licensed Product in the Territory; (ii) all Company Sole Inventions, Joint Inventions, and all intellectual property rights related to such Company Sole Inventions or Joint Inventions; and (iii) all agreements that are between the Company and any Affiliate, or Third Party, and that relate to the Development, manufacture, or commercialization of any Licensed Products; and
3. The Company may, after the effective date of such termination and continuing for a period not to exceed twelve (12) months thereafter, sell all completed Licensed Products, and any Licensed Products in the process of manufacture at the time of such termination, and sell the same, provided that the Company:
   1. notifies Licensor of its decision within thirty (30) days after the date it receives a notice of termination by Licensor or the date it provides a notice of termination to Licensor, as the case may be;
      * 19 -



1. pays or causes to be paid to Licensor the royalties and other payments thereon as required by Article 6 of this Agreement; and
2. submits the reports required by Article 7.

10.5.2 If the Company does not elect pursuant to Section 10.5.1 to sell-off or distribute, as applicable, any existing inventory of

Licensed Product, the Company shall, at Licensor’s election, either:

1. sell all existing inventory of Licensed Product to Licensor at fair market value; or
2. destroy all remaining inventory of Licensed Product in accordance with Applicable Laws and provide Licensor with written proof of destruction sufficient to comply with Applicable Laws.

**10.6 Wind-Down by the Company**. Upon any termination of this Agreement, the Company will (a) responsibly wind-down, in accordance withaccepted pharmaceutical industry norms and ethical practices, any on-going clinical trials for which it has responsibility hereunder in which patient dosing has commenced; or (b) at Licensor’s sole discretion, transfer to Licensor or its designee such clinical trial to the extent permitted under Applicable Laws and accepted pharmaceutical industry norms and ethical practices. The Company will be responsible for any costs associated with such wind-down mentioned under the foregoing subsections (a) and (b).

**10.7 Partial Termination**. Upon the early termination of this Agreement by either Party in respect of a country, the terms of Section 10.5 shall apply inrespect of such country.

**10.8 Survival**. Upon termination of this Agreement for any reason, nothing herein shall be construed to release either Party from any obligation thatmatured prior to the effective date of such termination or obligations under Articles 3 and 4. The following shall survive termination for any reason: Sections 2.3 and 3.2 and Articles 1, 9, 10, 11, 12, 13, 15, and 16.

**10.9 Bankruptcy**. All rights and licenses granted under or pursuant to this Agreement by a Party to the other Party are, and otherwise will be deemedto be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties agree that a Party that is a licensee of such rights under this Agreement will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws.

**Article 11**

**Infringement and Other Actions**

**11.1 Notice of Infringement of IP Rights**. The Company and Licensor shall promptly provide written notice, to the other Party, of any allegedinfringement or any challenge or threatened challenge to the validity, enforceability or priority of any of the IP Rights, and the Parties will provide each other with any available evidence of such infringement, challenge or threatened challenge by a Third Party of the IP Rights.

**11.2 Enforcement of IP Rights**. During the Term of this Agreement, the Company shall have the right, but not the obligation, at its own expense andutilizing counsel of its choice, to enforce the IP Rights against any alleged infringers/misappropriators and, subject to Section 11.3, to defend against any alleged infringement or misappropriation by the Company of Third Party intellectual property rights. In furtherance of such right, Licensor hereby agrees that the Company may join the Licensor as a party in any such suit at the Company’s own cost and expense. The Company shall indemnify and hold Licensor harmless against any costs, expenses or liability that may be found or assessed against Licensor in any such suit other than resulting from Licensor’s gross negligence or willful misconduct. Any recovery of damages pursuant to this Section 11.2 shall be allocated pursuant to Section 11.4 below.

- 20 -



**11.3 Infringement by Licensed Product**. In the event that a claim or suit is asserted or brought against the Company alleging that the manufacture orsale of any Licensed Product by the Company, an Affiliate of the Company, or any Sublicensee, or the use of such Licensed Product by any customer of any of the foregoing, infringes proprietary rights of a Third Party, the Company shall give written notice thereof to Licensor. The Company may, in its sole discretion, modify such Licensed Product to avoid such infringement and/or may settle on terms that it deems advisable in its sole discretion, subject to Section 11.2, and provided that the terms of such settlement shall not conflict with the Company’s obligations to Licensor pursuant to this Agreement. The Company shall have the right, but not the obligation, to defend any such claim or suit. In the event the Company elects not to defend such suit, Licensor shall have the right, but not the obligation to do so, subject to Section 11.2, at its sole expense.

**11.4 Allocation of Damages Recovered**. Any recovery of damages by the Company, in any such suit under Section 11.2 or 11.3, shall be applied firstin satisfaction of any unreimbursed expenses and legal fees of the Company and Licensor relating to the suit. The balance remaining from any such recovery shall be allocated as follows: sixty percent (60%) to the Company, and forty percent (40%) to Licensor.

**11.5 Cooperation.** In any suit to enforce and/or defend the IP Rights pursuant to this Agreement, the Party not in control of such suit shall, at therequest and expense of the controlling Party, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like.

**11.6 Limitations.** Notwithstanding any other provision of this License Agreement, the Licensor shall not have any obligation to indemnify, reimburse,defend or otherwise compensate or protect the Company, for any matter under this Article 11, except to the extent arising from a breach of representations of the Licensor as set forth in Section 12.2, and then only in accordance with and to the extent of, Article 13.

**Article 12**

**Representations, Warranties and Covenants**

**12.1** **The Company’s Representations and Warranties**. The Company represents and warrants to Licensor, as of the Effective Date, that:

12.1.1 The Company is a corporation duly organized, validly existing and in good standing under the laws of Delaware. The Company has the requisite power and authority to execute and deliver this Agreement and the other agreements contemplated hereby to which it is a party and to consummate the transactions contemplated herein. The execution and delivery of this Agreement and the other agreements contemplated hereby to which the Company is a party and the performance and consummation of the transactions contemplated herein by the Company have been duly authorized by all necessary action on the part of the Company. This Agreement and the other agreements contemplated hereby to which the Company is a party have been duly executed and delivered by the Company and, subject to the due authorization, execution and delivery of such agreements by the other parties thereto, this Agreement and such other agreements contemplated hereby constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforcement may be affected by bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditor’s rights generally and except for general principles of equity.

12.1.2 The execution and delivery of this Agreement and the other agreements contemplated hereby do not, and the consummation of the transactions contemplated hereby and thereby will not, (i) conflict with, or result in any violation or breach of any provision of the organizational documents of the Company, (ii) conflict with or violate any Applicable Laws of any U.S. Federal, state, foreign or local government or any court, tribunal, administrative agency or commission or other Governmental Authority, Regulatory Authority, Competent Authority, body or agency, including any self-regulatory organization (the “**Governmental** **Authorities**”) applicable to the Company or any of its assets or operations or any permit applicable to the Company or (iii)result in (x) any violation or breach of, constitute (with or without notice or lapse of time or both) a default under or conflict with (or give rise to a right of termination, amendment, cancellation or acceleration of any material obligation or loss of any benefit under) the provisions of any lease, contract or other agreement to which the Company is a party or by which it or any of its properties or assets is otherwise bound or (y) the imposition of any lien, pledge, hypothecation, mortgage, security interest, claim, lease, charge, option, right of first refusal or first offer, easement, servitude, transfer restriction, voting requirement or any other encumbrance, restriction or limitation on any of the properties or assets of the Licensor.

- 21 -



12.1.3 No consent, approval or authorization of, or declaration or filing with, any Governmental Authority or Person (a “**Consent**”) is required on the part of the Company in connection with its execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby.

12.1.4 As of the Effective Date, the Company has disclosed to Licensor all data, publications, and studies of which the Company is in possession of and that relate to the Licensed Product (or its research, Development, manufacture, or commercialization).

12.1.5 As of the Effective Date, the Company has not executed, or is not negotiating, any term sheets, option agreements, or other agreements that are with any Third Party and that relate to the Licensed Product (or its research, Development, manufacture, or commercialization).

**12.2** **Licensor’s Representations and Warranties**. Licensor represents and warrants, to Licensor’s knowledge (without any duty of inquiry) as of the

Effective Date, that:

12.2.1 The Licensor is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Licensor has the requisite power and authority to execute and deliver this Agreement and the other agreements contemplated hereby to which it is a party and to consummate the transactions contemplated herein. The execution and delivery of this Agreement and the other agreements contemplated hereby to which the Licensor is a party and the performance and consummation of the transactions contemplated herein by the Licensor have been duly authorized by all necessary action on the part of the Licensor. This Agreement and the other agreements contemplated hereby to which the Licensor is a party have been duly executed and delivered by the Licensor and, subject to the due authorization, execution and delivery of such agreements by the other parties thereto, this Agreement and such other agreements contemplated hereby constitute valid and binding obligations of the Licensor, enforceable against the Licensor in accordance with their respective terms, except as such enforcement may be affected by bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditor’s rights generally and except for general principles of equity.

12.2.2 The execution and delivery of this Agreement and the other agreements contemplated hereby do not, and the consummation of the transactions contemplated hereby and thereby will not, (i) conflict with, or result in any violation or breach of any provision of the organizational documents of the Licensor, (ii) conflict with or violate any Applicable Laws of any Governmental Authorities applicable to the Licensor or any of its assets or operations or any permit applicable to the Licensor or (iii) result in

1. any violation or breach of, constitute (with or without notice or lapse of time or both) a default under or conflict with (or give rise to a right of termination, amendment, cancellation or acceleration of any material obligation or loss of any benefit under) the provisions of any lease, contract or other agreement to which the Licensor is a party or by which it or any of its properties or assets is otherwise bound or (y) the imposition of any lien, pledge, hypothecation, mortgage, security interest, claim, lease, charge, option, right of first refusal or first offer, easement, servitude, transfer restriction, voting requirement or any other encumbrance, restriction or limitation on any of the properties or assets of the Licensor.

12.2.3 No Consent is required on the part of the Licensor in connection with its execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby.

12.2.4 Licensor owns all right, title, and interest in, or has exclusive license rights in, the Licensed Products, and IP Rights, but only to the extent validly granted to it under the Initial License, free and clear of all liens, charges, encumbrances or other restrictions or limitations of any kind whatsoever granted or incurred by, or at the direction of, Licensor.

12.2.5 There are no agreements, licenses, options, restrictions, liens, rights of Third Parties, disputes, royalty obligations, proceedings or claims relating to, affecting, or limiting Licensor’s ability to grant the Company the licenses granted under this Agreement.

- 22 -



12.2.6 Licensor has not received any notice that: (i) the IP Rights and Licensed Products infringe or misappropriate the intellectual property rights of any Third Party; or (ii) the IP Rights are invalid and unenforceable.

12.2.7 No Third Party has infringed or misappropriated or is infringing or misappropriating the IP Rights.

**12.3 DISCLAIMER. The Company has received, reviewed and done diligence to its satisfaction with respect to the Initial License and all property, rights and matters related thereto. EXCEPT AS SET FORTH ABOVE IN SECTIONS 12.2.1 – 12.2.7, LICENSOR, ITS AFFILIATES, AND THEIR DIRECTORS, OFFICERS, EMPLOYEES, AND AGENTS, MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED ON THE INITIAL LICENSE, THE IP RIGHTS, THE LICENSED PRODUCT, THE CONFIDENTIAL INFORMATION, OR THEIR USE BY THE COMPANY, ITS AFFILIATES, OR ANY SUBLICENSEES. IN PARTICULAR, AND WITHOUT LIMITING THE FOREGOING, NO WARRANTIES, EXPRESS OR IMPLIED ARE OFFERED AS TO: (I) THE MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THE IP RIGHTS, THE LICENSED PRODUCT, AND/OR THE CONFIDENTIAL INFORMATION PROVIDED TO COMPANY (INCLUDING THE AFFILIATES) UNDER THIS AGREEMENT; (II) THE SUCCESSFUL DEVELOPMENT OR COMMERCIALIZATION OF THE LICENSED PRODUCT; OR (III) THE NON-INFRINGEMENT (OR MISAPPROPRIATION) OF ANY THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS THROUGH THE RESEARCH, DEVELOPMENT, MANUFACTURE, OR COMMERCIALIZATION OF THE LICENSED PRODUCT.**

**12.4 The Company’s Covenant.** The Company covenants to Licensor that, as of the Effective Date and continuing throughout the Term, the Companywill perform all of its obligations under this Agreement.

**Article 13**

**Indemnity**

**13.1 Indemnity Obligations of Licensor**. Licensor shall indemnify, hold harmless, and defend the Company and its Affiliates and their respectivestockholders, members, managers, officers, directors, employees, agents, successors and assigns (the “**Company Indemnitees**”) against, and shall hold them harmless from, any and all losses, liabilities, damages, claims (including Third Party Claims), charges, interest, penalties, taxes, diminution in value, costs and expenses (including legal, consultant, accounting and other professional fees, and fees and costs incurred in enforcing rights under this Article 13) (collectively, “**Losses**”) resulting from, arising out of, or incurred by any Company Indemnitee in connection with, or otherwise with respect to:

13.1.1 the breach of any representation and warranty by Licensor contained in this Agreement;

13.1.2 any breach of any covenant or agreement of Licensor contained in this Agreement or any certificate or other document furnished, or to be furnished, to any Company Indemnitee in connection with the transactions contemplated by this Agreement; or

13.1.3 any claim of harm caused to any Third Party by use of any Licensed Product that is provided, sold or distributed by Licensor or any of its Affiliates outside the Territory.

**13.2 Indemnity Obligations by the Company**. The Company shall indemnify, hold harmless and defend Licensor and its Affiliates and theirrespective stockholders, members, managers, officers, directors, employees, agents, successors and assigns (the “**Licensor Indemnitees**”) against, and shall hold them harmless from, any and all Losses in the Territory resulting from, arising out of, or incurred by any Licensor Indemnitee in connection with, or otherwise with respect to:

13.2.1 the breach of any representation and warranty by the Company contained in this Agreement;

13.2.2 any breach of any covenant or agreement of the Company contained in this Agreement;

- 23 -



13.2.3 any claim of harm caused to any Third Party by the use of any Licensed Product that is provided, sold, manufactured, or distributed by the Company or any Affiliate, Sublicensee, distributor, contractor, or agent of the Company, in the Territory; or

13.2.4 the negligence, gross negligence, or willful misconduct of any Company Indemnitee.

**13.3 Indemnity Procedure; Insurance13.4.** In the event that any indemnitee receives notice of the assertion of any claim or the commencement of anyaction, suit or proceeding, claim, arbitration, litigation or investigation (an “**Action**”) by a Third Party in respect of which indemnity may be sought under the provisions of this Article 13 (“**Third Party Claim**”), the indemnitee shall notify the indemnitor of such Third Party Claim. The indemnitor shall have the right to defend, conduct and control the defense of the Third Party Claim (“**Third Party Defense**”) with counsel of its choice at the expense of the indemnitor; provided, however, that the indemnitee shall have the right, at its expense, to participate in (but not control) such Third Party Defense. The indemnitor shall conduct the Third Party Defense actively and diligently, and the indemnitee will provide reasonable cooperation in the Third Party Defense. The indemnitor shall have the right to consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim in any manner and on such terms as it may deem appropriate without the consent of the indemnitee provided, however, that no settlement shall be agreed to which admits to any wrongdoing or fault on behalf of indemnitee, or provides for the imposition of any obligation on the indemnitee other than the payment of money on the indemnitee’s behalf by the indemnitor. Furthermore, each Party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 13. Each Party shall provide the other Party with written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, non-renewal or material change in such insurance.

**13.5 Exclusive Remedy13.6.** This Article 13is the sole and exclusive remedy of the Company with respect to any matter arising from or relating to thisLicense Agreement. In no event shall the aggregate amounts payable by Licensor to the Company exceed, without duplication, the amount set forth in Section 16.10.

**Article 14**

**Use of Names and Publication**

**14.1 Use of Name**. Nothing contained in this Agreement shall be construed as granting any right to the Company, its Affiliates, or Sublicensees to usein advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of Licensor or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of Licensor; provided that each Party may use the other’s name in various documents used for capital raising and financing without such prior written consent and where the use of such names may be required by Applicable Law.

**14.2 No Agency**. Nothing herein shall be deemed to establish a relationship of principal and agent between Licensor and the Company, nor any of theiragents or employees for any purpose whatsoever. This Agreement shall not be construed as creating a partnership between the Licensor and the Company, or as creating any other form of legal association or arrangement, which would impose liability upon one Party for the act or failure to act by the other Party, or that would allow one Party to bind the other Party.

**14.3 Publication**. Subject to Section 15.2, in the event that the Company desires to publish or disclose publicly, by written, oral or other presentation,any material information directly related to Licensed Products generated by Company or its Sublicensees (and not already in the public domain), this Agreement or the transactions contemplated hereby, then the Company shall notify Licensor in writing, confirmed by the Licensor, and/or by certified or registered mail (return receipt requested) of their intention at least thirty (30) days prior to any publication, disclosure, speech, lecture or other oral or written presentation at least thirty (30) days before any written or other publication or disclosure of such material information. Following receipt of such notice by the Licensor, the Company may not publish or disclose publicly, by written, oral, other presentation, any material information directly related to Licensed Product without express written approval of Licensor. The Company shall include with such notice a description of any proposed oral presentation or, in any proposed written or other disclosure, a current draft of such proposed disclosure or abstract.

- 24 -



**Article 15**

**Confidentiality**

**15.1 Confidentiality and Non-Use**. Any information that is disclosed by a Party to the other Party under this Agreement, that is marked as“CONFIDENTIAL”, and that directly relates to the Licensed Product shall be deemed the “Confidential Information” of the disclosing Party. Each Party covenants and agrees that it will use the Confidential Information of the other Party solely for performing its obligations, and exercising its rights, under this Agreement and shall not use any such Confidential Information for any other purpose unrelated to this Agreement. Further, each Party covenants and agrees that it will hold all of the other Party’s Confidential Information in confidence, and shall not disclose same to any Third Party, during the Term and for a period of five (5) years after the termination or expiration of this Agreement. Each Party shall exercise, with respect to the Confidential Information of the other Party, the same degree of care as the Party exercises with respect to its own confidential or proprietary information of a similar nature, but in any event no less than reasonable care, and shall not disclose such Confidential Information of the other Party or permit its disclosure to any Third Party (except to those of its employees, consultants, or agents who are bound by the same obligation of confidentiality of this Agreement). However, the foregoing undertakings of non-use and confidentiality shall not apply to any specific Confidential Information of a disclosing Party that the receiving Party can demonstrate:

1. the receiving Party receives at any time from a third-party lawfully in possession of same and having the right to disclose same;
2. is, as of the date of this Agreement, in the public domain, or subsequently enters the public domain through no fault of the receiving Party;
3. is independently developed by the receiving Party as demonstrated by written evidence without reference or access to any Confidential Information disclosed to the receiving Party by the disclosing Party; or
4. is disclosed pursuant to the prior written approval of the disclosing Party.

Further, notwithstanding the foregoing, a Party may disclose specific Confidential Information of the other Party to the extent that such disclosure is required pursuant to Applicable Law or legal process (including, without limitation, to a Governmental Authority) provided, in the case of disclosure pursuant to legal process, reasonable prior notice of the impending disclosure is provided to the non-disclosing Party.

**15.2 Securities Filings**. In the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any stateor other jurisdiction: (a) any registration statement or any other disclosure document which describes or refers to the terms and conditions of this Agreement; (b) a copy of this Agreement; or (c) a request for confidential treatment of this Agreement, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing and any related correspondence and/or memorandum, and shall use Commercially Reasonable Efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party requests be kept confidential, and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed or required to be disclosed. No such notice shall be required under this Section 15.2 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party.

- 25 -



**Article 16**

**Miscellaneous Provisions**

**16.1 Assignment**. The Company shall have the right to assign (including by way of merger or operation of law) this Agreement (or delegate itsobligations under this Agreement), in whole as part of a sale of all of Company’s business but not otherwise, to Third Parties, or an Affiliate of the Company, on the conditions that: (a) the Company is not in breach of any of its payment obligations, or material breach of any other obligation, under this Agreement at the time of such assignment; (b) the assignee has and will have, or has reasonable access to, adequate resources to perform its obligations under this Agreement; and (c) such assignment agreement is in writing and includes an agreement by the assignee, acknowledging that for purpose of the assignment it shall, and be deemed to, succeed to all obligations, duties, and rights of the Company under this Agreement, for the express benefit of the Licensor. The Company shall remain primarily responsible for performance of the obligations of “the Company” ( as referred to under this Agreement) under and pursuant to this Agreement and for any failure of such assignee to pay or perform the same when due. The Company shall provide Licensor with a copy of any such permitted assignment within thirty (30) days prior to its execution. This Agreement and the rights and duties appertaining hereto (including the right to receive royalties or milestone payments under this Agreement) may be assigned or transferred by Licensor at Licensor’s sole discretion (without obtaining the written consent of the Company). Any purported assignment in violation of this Section 16.1 shall be null, void, and of no effect. No assignment shall relieve either Party of responsibility for the performance of any obligation that accrued before the effective date of assignment. This Agreement is binding upon the permitted successors and assigns of the Parties. Any purported assignment in violation of this Section shall be null, void, and of no effect.

**16.2 Binding Nature and Inurnment**. This Agreement will not be binding upon the Parties until it has been signed below on behalf of each Party, inwhich event, it shall be effective as of the Effective Date. As of the Effective Date, this Agreement is binding upon and inures to the benefit of the Parties and their respective permitted successors and assigns.

**16.3 Compliance with Applicable Laws**. The Company shall observe all Applicable Laws with respect to the making, manufacture, use, sale, offer forsale, export and/or import of Licensed Product and related technical data to foreign countries, including the regulations of Regulatory Authorities.

**16.4 Counterparts; Facsimile**. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all ofwhich together shall constitute one and the same instrument. This Agreement may be signed and delivered to the other Party by facsimile signature or as a pdf attachment to an email; such transmission will be deemed a valid signature.

**16.5 Entire Agreement; Amendment**. The Parties hereto acknowledge that this Agreement, including the Exhibits, Schedules and documentsincorporated by reference, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof, and shall not be subject to any change of modification except by the execution of a written instrument subscribed to by the Parties and shall supersede all previous communications, representations or understandings, either oral or written, between the Parties relating to the subject matter hereof. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of each of the Parties.

**16.6 Force Majeure**. Neither Party is responsible for delays resulting from causes beyond its reasonable control, including fire, explosion, flood, war,strike, act of terrorism, epidemic, pandemic, or riot, provided that the nonperforming Party uses Commercially Reasonable Efforts to avoid or remove those causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever the causes are removed.

**16.7 Further Assurances**. From time to time during the Term, at the request of either Party, and without any further consideration, the other Party shallexecute and deliver such documents (including any instruments of sale, merger, and transfer) and take such other action as the requesting Party may reasonably request to the extent necessary to consummate more effectively the transactions contemplated hereby.

- 26 -



**16.8 Interpretation**. Except where the context expressly requires otherwise: (a) the use of any gender herein shall be deemed to encompass referencesto either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa); (b) the words “include”, “includes”, and “including” shall be deemed to be followed by the phrase “without limitation”; (c) the word “will” shall be construed to have the same meaning and effect as the word “shall”; (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (e) any reference herein to any person or entity shall be construed to include the person’s or entity’s successors and assigns; (f) the words “herein”, “hereof”, and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof; (g) all references herein to Sections, Exhibits, or Schedules shall be construed to refer to Sections, Exhibits, or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto; (h) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise, including by e-mail; (j) unless stated otherwise, references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof; (k) the term “or” shall be interpreted in the inclusive sense commonly associated with the term “and/or”; (l) each Party has used its legal counsel in the negotiation of this Agreement, and the Agreement will not be construed against either Party as the drafter; and (m) references to any Sections include Sections and subsections that are part of the related Section (e.g., a section numbered “Section 2.1” would be part of “Section 2”, and references to “Section 2.1” would also refer to material contained in the subsection described as “Section 2.1.1(a)”).

**16.9 Law; Jurisdiction**. This Agreement shall be construed, governed, interpreted and applied in accordance with the laws of the State of New York,without regard to principles of conflicts of laws.

**16.10 No Consequential Damages; Liability Limit**. EXCEPT WITH REGARD TO DAMAGES ARISING FROM BREACH OF Article 15 ANDANY DUTY TO INDEMNIFY FOR INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES RECOVERED BY A THIRD PARTY, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES INCURRED BY EITHER PARTY UNDER THIS AGREEMENT OR OTHERWISE. NOTWITHSTANDING ANYTHING TO THE CONTRARY, IN NO EVENT SHALL LICENSOR’S CUMULATIVE LIABILITY EXCEED THE AMOUNT OF THE PAYMENTS RECEIVED BY LICENSOR FROM THE COMPANY (IN STOCK OR CASH) IN THE TWELVE (12) MONTHS PRECEDING THE DATE OF THE CLAIM FOR WHICH THE LIABILITY RELATES. THE PROVISIONS OF THIS SECTION 16.10 SHALL SURVIVE THE EXPIRATION OR TERMINATION OF THIS AGREEMENT.

**16.11 Payments, Notices and Other Communications**. Any payment, notice or other communication required or permitted to be given pursuant to thisAgreement shall be in writing and sent by certified first class mail, postage prepaid, by hand delivery or by facsimile if confirmed in writing, in each case effective upon receipt, at the addresses below or as otherwise designated by written notice given to the other Party:

In the case of Licensor:

Cortice Biosciences

1345 Avenue of the Americas

42nd Floor

New York, NY 10105

Attn: Michael Weiser/Jason Stein

Email: mweiser@actin.com

Cc: jstein@actin.com

- 27 -



With a copy to:

O’Melveny & Myers LLP

Two Embarcadero Center, 28th Floor

San Francisco, CA 94111

Attention: Geoff Kuziemko

Email: gkuziemko@omm.com

In the case of the Company:

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, Texas 77027

Attention: CEO

Telephone No. (800) 946-9185

E-mail: Notices@CNSPharma.com

With a copy to:

ArentFox Schiff LLP

1717 K Street, NW

Washington, DC 20006

E-mail: cavas.pavri@afslaw.com

Facsimile No.: (202) 857-6395

Attention: Cavas Pavri, Esq.

**16.12 Payment of Own Fees and Expenses**. Each of the Company and Licensor shall be responsible for their own expenses relating to the preparationand consummation of this Agreement.

**16.13 Severability**. The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to beinvalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.

**16.14 Waiver**. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall notconstitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. Any waiver of any rights or failure to act in a specific instance relates only to that instance and is not an agreement to waive any rights or fail to act in any other instance.

***Signature page follows.***

- 28 -



**IN WITNESS WHEREOF**, the Parties hereto have executed this Agreement by proper persons, duly authorized, as of the date below. The Partiesacknowledge that the signature date(s) may differ from the Effective Date.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CNS PHARMACEUTICALS, INC.** | | | **CORTICE BIOSCIENCES, INC.** | | |
| By: /s/ John Climaco | | | By: /s/ Michael Weiser | | |
|  |  |  |  |  |  |
| Name: John Climaco | | | Name: Michael Weiser | | |
| Tittle: Chief Executive Officer | | | Tittle: Director | | |
| Date: July 29, 2024 | | | Date: July 29, 2024 | | |

- 29 -



**Exhibit 10.2**

**STOCK PURCHASE AGREEMENT**

**Between**

**CNS PHARMACEUTICALS, INC., AND**

**CORTICE BIOSCIENCES, INC.,**

**Dated: July 29, 2024**



|  |  |  |
| --- | --- | --- |
|  | **TABLE OF CONTENTS** |  |
|  |  | **Page** |
| Article I | DEFINITIONS AND RULES OF CONSTRUCTION | 1 |
| 1.1 | Definitions | 1 |
| 1.2 | Rules of Construction | 4 |
| Article II | PURCHASE AND SALE; CLOSING | 5 |
| 2.1 | Closing | 5 |
| 2.2 | Purchase and Sale | 5 |
| 2.3 | Transactions at the Closing | 6 |
| 2.4 | Issuance under the License | 6 |
| Article III | REPRESENTATIONS AND WARRANTIES OF THE BUYER | 6 |
| 3.1 | Organization and Power | 6 |
| 3.2 | Authorization and Enforceability | 6 |
| 3.3 | No Violation | 7 |
| 3.4 | Governmental Authorizations and Consents | 7 |
| 3.5 | Buyer Status | 7 |
| Article IV | REPRESENTATIONS AND WARRANTIES OF ISSUER | 7 |
| 4.1 | Organization and Power | 7 |
| 4.2 | Authorization and Enforceability | 7 |
| 4.3 | No Violation | 8 |
| 4.4 | Governmental Authorizations and Consents | 8 |
| 4.5 | Litigation | 8 |
| 4.6 | Valid Issuance of Stock Consideration | 8 |
| 4.7 | Public Filings | 8 |
| Article V | COVENANTS | 9 |
| 5.1 | Public Announcements | 9 |
| 5.2 | Lock-Up | 9 |
| 5.3 | Solicitation of Issuer Stockholder Approvals | 10 |
| Article VI | CONDITIONS TO CLOSING | 10 |
| 6.1 | Conditions to All Parties’ Obligations | 10 |
| 6.2 | Conditions to Issuer’s Obligations | 10 |
| 6.3 | Conditions to Buyer’s Obligations | 11 |
| Article VII | INDEMNIFICATION; SURVIVAL | 11 |
| 7.1 | Indemnification | 11 |
| 7.2 | Interest | 12 |

- i -



|  |  |  |
| --- | --- | --- |
|  | **TABLE OF CONTENTS** |  |
|  | **(continued)** |  |
|  |  | **Page** |
| Article VIII | TERMINATION | 12 |
| 8.1 | Termination | 12 |
| 8.2 | Effect of Termination | 12 |
| Article IX | MISCELLANEOUS | 12 |
| 9.1 | Amendment | 12 |
| 9.2 | Expenses | 12 |
| 9.3 | Notices | 12 |
| 9.4 | Governing Law | 13 |
| 9.5 | Entire Agreement | 13 |
| 9.6 | Severability | 13 |
| 9.7 | Cumulative Remedies; No Waiver | 14 |
| 9.8 | Parties in Interest; Limitation on Rights of Others | 14 |
| 9.9 | Assignability | 14 |
| 9.10 | Disclosure Schedules | 14 |
| 9.11 | Jurisdiction; Court Litigations; Waiver of Jury Trial; Service of Process | 14 |
| 9.12 | Recovery of Fees by Prevailing Party | 15 |
| 9.13 | No Other Duties | 15 |
| 9.14 | Reliance on Counsel and Other Advisors | 15 |
| 9.15 | Remedies | 15 |
| 9.16 | Post Closing Specific Performance | 15 |
| 9.17 | Counterparts | 15 |
| 9.18 | Further Assurance | 15 |
| 9.19 | Securities Filings | 16 |

- ii -



**STOCK PURCHASE AGREEMENT**

STOCK PURCHASE AGREEMENT, dated as of July 29, 2024, by and among CNS Pharmaceuticals, Inc. a Nevada corporation (“Issuer”), and Cortice Biosciences, Inc., a Delaware corporation (the “Buyer”). The Buyer and Issuer are each sometimes referred to herein individually as a “Party” and together as the “Parties”.

WHEREAS, Buyer desires to purchase from Issuer, and Issuer desires to sell to the Buyer, the Stock Consideration (as defined herein) upon the terms and subject to the conditions hereinafter set forth.

NOW THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements contained in this Agreement, and intending to be legally bound hereby, the Parties hereto agree as follows:

**ARTICLE I**

**DEFINITIONS AND RULES OF CONSTRUCTION**

1.1 Definitions.

As used in this Agreement, the following terms shall have the meanings set forth below:

“Affiliate” means, as to any Person, any other Person that, directly or indirectly, is in control of, is controlled by, or is under common control with, such Person. For purposes of this definition, “control” of a Person means the power, directly or indirectly, either to (a) vote 50% or more of the securities having ordinary voting power for the election of directors of such Person or (b) direct or cause the direction of the management and policies of such Person, whether by contract or otherwise.

“Agreement” means this Stock Purchase Agreement, as it may be amended from time to time.

“Ancillary Documents” means the License Agreement, in the form attached hereto as Exhibit A, and such other documents being executed and delivered in connection with the Closing as provided in Section 6.1.

“Business Day” means any day other than a Saturday, Sunday or day on which banks are closed in New York, New York. If any period expires on a day which is not a Business Day or any event or condition is required by the terms of this Agreement to occur or be fulfilled on a day which is not a Business Day, such period shall expire or such event or condition shall occur or be fulfilled, as the case may be, on the next succeeding Business Day.

“Buyer” has the meaning set forth in the Preamble.

“Buyer Disclosure Schedule” means the disclosure schedule of even date herewith delivered by Buyer to the Issuer in connection with the execution and delivery of this Agreement.

“Buyer Material Adverse Effect” means any change or effect, event, circumstance, occurrence, state of facts or development that: (a) would reasonably be likely to have a material adverse effect on the business, operations or financial condition of the Buyer, or (b) would prevent the Buyer or Issuer from consummating the Contemplated Transactions; provided, that none of the following events, changes, developments, effects, conditions, circumstances, matters, occurrences or state of facts shall be taken into account in determining whether there has been or may be a Buyer Material Adverse Effect: (i) any change or development in United States financial or securities markets, general economic or business conditions, or political or regulatory conditions; (ii) any act of war, armed hostilities or terrorism; (iii) any change or development in the pharmaceuticals industry; (iv) any change in Law or GAAP or the interpretation or enforcement of either; (v) any termination or failure to renew by any Governmental Authority of any Permit of the Buyer;

1. the announcement, execution or consummation of this Agreement or any of the Ancillary Documents or the consummation of any of the Contemplated Transactions; or (vii) any change resulting from the failure of Issuer to reasonably consent to any acts or actions requiring Issuer’s consent under this Agreement and for which the Buyer has sought such consent except, in the case of clauses (iii) or (iv), to the extent such events, changes, developments, effects, conditions, circumstances, matters, occurrences or state of facts have a materially disproportionate effect on the Buyer (and which such materially disproportionate effect is durationally significant) relative to other Persons engaged in the pharmaceuticals industry.
   * 1 -



“Buyer Fundamental Representations” means the representations and warranties set forth in Section 3.1 (Organization), and Section 3.2 (Authorization and Enforceability).

“Closing” has the meaning set forth in Section 2.1.

“Closing Date” has the meaning set forth in Section 2.1.

“Closing Stock Consideration” has the meaning set forth in Section 2.2.

“Contemplated Transactions” means: (a) the transactions contemplated by this Agreement (including the purchase and sale of the Closing Stock Consideration); and (b) the execution and delivery of the Ancillary Documents at the Closing.

“Consent” means any consent, approval, filing, registration, notification, Permit, Order or authorization.

“Contract” means any written agreement, license, contract, arrangement, understanding, obligation or commitment to which a Party is bound.

“Disposition”, “Disposed of”, or “Dispose of” means any sale, contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any shares of Issuer Common Stock, including, without limitation: (a) any “short sale,” hedging or similar arrangement; (b) swap; or (c) any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of Issuer Common Stock, whether any such swap or transaction is to be settled by delivery of securities, in cash or otherwise.

“Equity Securities” of any Person means any and all shares of capital stock, warrants or options of such Person, and all securities exchangeable for or convertible or exercisable into, any of the foregoing.

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

“Fundamental Representations” means the Issuer Fundamental Representations and the Buyer Fundamental Representations.

“GAAP” means generally accepted accounting principles as set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States.

“Governing Documents” means, with respect to any particular Person: (a) if a corporation, the articles or certificate of incorporation and the bylaws of such entity; (b) if a general partnership, the partnership agreement and any statement of partnership; (c) if a limited partnership, the limited partnership agreement and the certificate of limited partnership; (d) if a limited liability Buyer, the articles or certificate of organization or formation and the operating agreement or limited liability Buyer agreement; (e) if another type of Person, any other charter or similar document adopted or filed in connection with the creation, formation or organization of such Person; (f) all equity holders’ agreements, voting agreements, voting trust agreements, joint venture agreements, registration rights agreements or other agreements or documents relating to the organization, management or operation of such Person or relating to the rights, duties and obligations of the equity holders of such Person; and (g) any amendment or supplement to any of the foregoing.

“Governmental Authority” means any nation or government, any foreign or domestic federal, state, county, municipal or other political instrumentality or subdivision thereof and any foreign or domestic entity or body exercising executive, legislative, judicial, regulatory, administrative or taxing functions of or pertaining to government, including any court and any official of any of the foregoing.

- 2 -



“Governmental Consents” has the meaning set forth in Section 3.4.

“Issuer” has the meaning set forth in the Preamble.

“Issuer Common Stock” means the common stock, par value $0.001 per share, of Issuer.

“Issuer Disclosure Schedule” means the disclosure schedule of even date herewith delivered by Issuer to the Buyer in connection with the execution and delivery of this Agreement.

“Issuer Fundamental Representations” means the representations and warranties set forth in Section 4.1 (Organization and Power); Section 4.2 (Authorization and Enforceability); and Section 4.6 (Brokers or Finders).

“Issuer Material Adverse Effect” means any change or effect, event, circumstance, occurrence, state of facts or development that would prevent Issuer from consummating the Contemplated Transactions; provided, that none of the following events, changes, developments, effects, conditions, circumstances, matters, occurrences or state of facts shall be taken into account in determining whether there has been or may be a Issuer Material Adverse Effect: (a) any change or development in United States financial or securities markets, general economic or business conditions, or political or regulatory conditions; (b) any act of war, armed hostilities or terrorism; (c) any change or development in the pharmaceuticals industry; (d) any change in Law or GAAP or the interpretation or enforcement of either; (e) the announcement, execution or consummation of this Agreement or any of the Ancillary Documents or the consummation of any of the Contemplated Transactions; (f) any change resulting from the actions or failure to act of the Buyer; or (g) any change resulting from the failure of the Buyer to reasonably consent to any acts or actions requiring the Buyer’s consent under this Agreement and for which Issuer has sought such consent except, in the case of clauses (c) or (d), to the extent such events, changes, developments, effects, conditions, circumstances, matters, occurrences or state of facts have a materially disproportionate effect on Issuer (and which such materially disproportionate effect is durationally significant) relative to other Persons engaged in the pharmaceuticals industry.

“Laws” means all laws, Orders, statutes, codes, regulations, ordinances, orders, decrees, rules, or other requirements with similar effect of any Governmental Authority.

“Liability” means any liability, obligation, deficiency (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due) of every kind and description, including any liability for Taxes, and any liability arising under any Contract or undertaking.

“License Agreement” means the Exclusive License Agreement for TPI-287 between the Buyer and the Issuer.

“Lien” means, with respect to any asset (including any security), any option, claim, mortgage, lien, security interest, pledge, charge or other encumbrance or restrictions of any kind in respect of such asset, other than any license of, option to license, or covenant not to assert claims of infringement, misappropriation or other violation with respect to, intellectual property rights.

“Litigation” any civil, criminal or administrative demand, claim, action, dispute, cause of action, arbitration, audit, hearing, investigation, inquiry, litigation, suit, charge, complaint, grievance, allegation, indictment, assessment, or other proceeding

“Loss” or “Losses” means all claims, losses, liabilities, damages, costs and expenses, including, without limitation, reasonable attorneys’ fees, provided, that: (a) Losses shall not include special damages or punitive damages, in each case if and to the extent incurred by an Indemnified Person (as distinguished from such amounts incurred by a Third Party for which and to whom any Indemnified Person may be responsible under any Laws or under any Contracts providing for any Indemnified Person to provide indemnification of such amounts); and (b) for purposes of computing Losses incurred by an Indemnified Person, there shall be deducted an amount equal to the amount of any insurance proceeds, indemnification payments, contribution payments and reimbursements received by the Indemnified Person, and an amount equal to the amount of any Tax savings realized by the Indemnified Person as a result of the Loss.

- 3 -



“Order” means all judgments, orders, writs, injunctions, decisions, rulings, decrees, settlement agreements, consent agreements and awards of any Governmental Authority.

“Permit” means any license, permit, registration, variance, exemption, consent, waiver, authorization, right, certificate, franchise, order or approval, qualification, or similar document or authority, and all pending applications therefor or renewals thereof.

“Person” means any individual, person, entity, general partnership, limited partnership, limited liability partnership, limited liability company, corporation, joint venture, trust, business trust, cooperative, association, foreign trust or foreign business organization.

“Post-Closing Stock Consideration” means any newly issued shares of Issuer Common Stock to be issued to the Buyer pursuant to the terms of the License Agreement.

“Proxy Statement” means the proxy statement filed by Issuer with respect to the Shareholder Meeting for the purpose of soliciting proxies from Issuer shareholders to approve the NASDAQ Proposal.

“Registration Rights Agreement” means the Registration Rights Agreement to be executed at Closing by and between Issuer and Buyer .

“SEC” means the US Securities and Exchange Commission.

“Stock Consideration” means, collectively, the Closing Stock Consideration and the Post-Closing Stock Consideration.

“Tax” or “Taxes” means any U.S. federal, state, local or non-U.S. income, profits, franchise, gross receipts, license, environmental, customs duty, capital stock, severances, stamp, payroll, sales, employment, unemployment, social security (or similar), disability, use, property, withholding, excise production, registration, value added, occupancy, Transfer Taxes, alternative or add-on minimum, estimated, or other tax, duties or assessment of any nature whatsoever, including any interest, penalty or addition thereto, whether disputed or not.

“Third Party” means a Person other than Buyer and its Affiliates and Issuer and its Affiliates.

“Transfer Taxes” means all transfer, documentary, sales, use, stamp, registration and other such Taxes and fees (including any penalties and interest) incurred in connection with the Contemplated Transactions (including any transfer or similar Tax imposed by any Governmental Authority).

1.2 Rules of Construction.

Unless the context otherwise requires:

1. A capitalized term has the meaning assigned to it;
2. An accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;
3. Any reference in this Agreement or any Ancillary Document to any legislation or to any provision of any legislation shall include any amendment to, and any modification or re-enactment of, any legislative provision substituted therefor, and all regulations and statutory instruments issued thereunder or pursuant thereto.
   * 4 -



1. References in the singular or to “him,” “her,” “it,” “itself,” or other like references, and references in the plural or the feminine or masculine reference, as the case may be, shall also, when the context so requires, be deemed to include the plural or singular, or the masculine or feminine reference, as the case may be;
2. References to Articles and Sections and Exhibits shall refer to articles and sections and exhibits of this Agreement, unless otherwise specified;
3. The headings in this Agreement are for convenience and identification only and are not intended to describe, interpret, define, or limit the scope, extent or intent of this Agreement or any provision thereof;
4. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement; and
5. All monetary figures shall be in United States dollars unless otherwise specified; and
6. References to “including” in this Agreement means “including, without limitation,” whether or not so specified.

**ARTICLE II**

**PURCHASE AND SALE; CLOSING**

2.1 Closing.

The closing of the transactions contemplated by this Agreement (including the execution and delivery of the License Agreement and the Ancillary Documents) (the “Closing”) will take place over ZOOM at 4:00 P.M. NYC time on or before the fifth Business Day immediately following the day on which the last of the conditions set forth in Article VI (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions) are satisfied or waived in accordance with this Agreement, or on such other date as Issuer and Buyer’s Representative may otherwise agree, with delivery of documents to be made by hand or over night mail in advance or by electronic delivery, as appropriate. The day on which the Closing actually occurs is referred to herein as the “Closing Date.”

2.2 Purchase and Sale.

1. Subject to the terms and conditions set forth in this Agreement, and in reliance upon the representations, warranties, and covenants of the Issuer contained in this Agreement, at the Closing, Buyer shall purchase from Issuer, and Issuer shall issue and sell transfer and assign to Buyer, 573,368 newly issued shares of the Issuer Common Stock at the Closing (the “Initial Closing Stock Consideration”), and 43,330 newly issued shares of the Issuer Common Stock upon, and subject to, the receipt of the approval of the NASDAQ Proposal (the “Subsequent Closing Stock Consideration” and together with the Initial Closing Stock Consideration, the “Closing Stock Consideration”).
2. The specific number, class and issuer of any Stock Consideration to be issued pursuant to this Agreement and/or the License Agreement will be appropriately and equitably adjusted to reflect any stock split or combination, dividend, reorganization, reclassification, recapitalization, merger, business combination, exchange or readjustment of shares, or other similar event.
   * 5 -



2.3 Transactions at the Closing.

1. At the Closing, Issuer shall deliver to Buyer full and complete documentation evidencing the issuance to Buyer of the Closing Stock Consideration, which shall be in book-entry form, including all other documents and instruments of issuance or transfer necessary to vest in the Buyer with all of the right, title and interest in and to the Closing Stock Consideration as of the Closing Date, free and clear of all Liens, other than restrictions expressly provided under this Agreement and/or under applicable Laws.

2.4 Issuance of Post-Closing Stock Consideration under the License Agreement.

1. All Post-Closing Stock Consideration to be issued under the License Agreement shall be issued in shares of Issuer Common Stock of the same class and series, and having the same rights, as the Closing Stock Consideration.
2. At the time of the issuance of any Post-Closing Stock Consideration: (i) Issuer shall deliver to Buyer full and complete documentation evidencing the issuance thereof to Buyer, which shall be in book-entry form, including all other documents and instruments of issuance or transfer necessary to vest in the Buyer with all of the right, title and interest in and to such shares as of the date of issuance, free and clear of all Liens, other than restrictions expressly provided under this Agreement and/or under applicable Laws; and (ii) each of the representations and warranties of the Issuer as set forth in Article IV hereof shall be true and correct as of the time of such issuance, and an authorized executive officer of the Issuer shall execute and deliver to Buyer an officer’s certificate so certifying.

**ARTICLE III**

**REPRESENTATIONS AND WARRANTIES OF THE BUYER**

Except as set forth in the Buyer Disclosure Schedule (it being agreed that any matter disclosed in the Buyer Disclosure Schedule with respect to any section of this Agreement shall be deemed to have been disclosed with respect to any other section to the extent the applicability thereto is reasonably apparent), Buyer hereby represents and warrants to Issuer as follows:

3.1 Organization and Power. The Buyer is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being conducted. Section 3.1 of the Buyer Disclosure Schedule lists all jurisdictions in which the Buyer is qualified to do business. The Buyer is duly qualified or licensed to do business and in good standing in each jurisdiction in which the property owned, leased or operated by it or the nature of the business conducted by it makes such qualification or licensing necessary, except where the failure to be so duly qualified or in good standing would not, individually or in the aggregate, have a Buyer Material Adverse Effect. Prior to the date of this Agreement, Buyer has delivered or made available to Issuer accurate and complete copies of its Governing Documents.

3.2 Authorization and Enforceability.

1. The Buyer has full corporate power and authority to execute and deliver this Agreement and each of the Ancillary Documents to which it is a party and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by the Buyer of this Agreement and each of the Ancillary Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, have been duly authorized by its board of directors and no other corporate action on the part of the Buyer is necessary to authorize the execution and delivery by the Buyer of this Agreement and each of the Ancillary Documents to which it is a party and the consummation by it of the transactions contemplated hereby and thereby. This Agreement and each of the Ancillary Documents to which the Buyer is a party have been duly executed and delivered by the Buyer and, assuming due and valid execution and delivery hereof and thereof by each other Party thereto, are valid and binding obligations of the Buyer, enforceable against it in accordance with their respective terms, except that (i) such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, affecting creditors’ rights generally and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.
   * 6 -



1. Except for matters specifically described in this Agreement, neither the execution, delivery or performance by the Buyer of this Agreement and each of the Ancillary Documents to which it is a party nor the consummation by the Buyer of the transactions contemplated hereby or thereby will: (i) violate or conflict with any provision of any Governing Document of the Buyer; (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation or acceleration) under, or result in the creation of any Lien upon any Equity Security or asset or property of the Buyer under any of the terms, conditions or provisions of, any material Contract to which the Buyer is a party or by which the Buyer or any of its properties or assets may be bound; (iii) violate any Law or (iv) require on the part of the Buyer any Consent from any Governmental Authority.

3.3 No Violation. The execution and delivery by the Buyer, of this Agreement and the Ancillary Documents to which the Buyer is a party, the performance by the Buyer of its obligations under this Agreement and the Ancillary Documents to which it is a party, and the consummation by the Buyer of the transactions contemplated hereby and thereby will not: (a) conflict with or violate any Governing Document of the Buyer; and (b) assuming that all Consents, approvals and authorizations contemplated by Section 3.4 have been obtained and all filings described therein have been made, conflict with or violate any Law applicable to the Buyer or by which its or any of their respective properties is bound or affected.

3.4 Governmental Authorizations and Consents. No Consent from any Governmental Authority (“Governmental Consents”) is required to be obtained or made by the Buyer in connection with the execution, delivery, performance, validity and enforceability of this Agreement or any Ancillary Documents to which the Buyer is, or is to be, a party or the consummation by the Buyer of the transactions contemplated hereby and thereby.

3.5 Buyer Status.

1. Buyer is, and on each date on which any Stock Consideration is or will be issued will be, an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act of 1933, as amended.
2. Buyer has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Issuer and has so evaluated the merits and risks of such investment. Buyer is able to bear the economic risk of an investment in the Issuer and, at the present time, is able to afford a complete loss of such investment.

**ARTICLE IV**

**REPRESENTATIONS AND WARRANTIES OF ISSUER**

Except as set forth in the Issuer Disclosure Schedule (it being agreed that any matter disclosed in the Issuer Disclosure Schedule with respect to any section of this Agreement shall be deemed to have been disclosed with respect to any other section to the extent the applicability thereto is reasonably apparent), Issuer hereby represents and warrants to Buyer as follows:

4.1 Organization and Power. Issuer is a corporation duly incorporated, validly existing and in good standing under the Laws of the state of Nevada and has full power and authority to execute, deliver and perform its obligations under this Agreement and the Ancillary Documents to which it is a party and to consummate the transactions contemplated hereby and thereby.

4.2 Authorization and Enforceability. The execution and delivery of this Agreement and the Ancillary Documents to which Issuer is a party, the performance by Issuer of its obligations under this Agreement and the Ancillary Documents to which it is a party, and the consummation by Issuer of the transactions contemplated hereby and thereby have been duly authorized by Issuer, and no other corporate proceedings on the part of Issuer (including, without limitation, any shareholder vote or approval) are necessary to authorize the execution and delivery of this Agreement and the Ancillary Documents to which Issuer is a party, the performance by Issuer of its obligations under this Agreement and the Ancillary Documents to which it is a party, or the consummation by Issuer of the transactions contemplated hereby and thereby. This Agreement is, and each of the Ancillary Documents to be executed and delivered at the Closing by Issuer will be at the Closing, duly authorized, executed and delivered by Issuer and constitute, or as of the Closing Date will constitute, valid and legally binding agreements of Issuer enforceable against Issuer, in accordance with their terms, subject to bankruptcy, insolvency, reorganization and other Laws of general applicability relating to or affecting creditors’ rights generally and to general equity principles.

- 7 -



4.3 No Violation. The execution and delivery by Issuer of this Agreement and the Ancillary Documents to which Issuer is a party, the performance by Issuer of its obligations under this Agreement and the Ancillary Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby will not: (a) conflict with or violate any provision of the Issuer’s Governing Documents; or (b) assuming that all consents, approvals and authorizations contemplated by Section 5.3 have been obtained and all filings described therein have been made, conflict with or violate in any material respect any Law applicable to Issuer or by which its properties are bound or affected.

4.4 Governmental Authorizations and Consents. No Governmental Consents are required to be obtained or made by Issuer in connection with the execution, delivery, performance, validity and enforceability of this Agreement or any Ancillary Documents to which Issuer is, or is to be, a party, or the consummation by Issuer of the transactions contemplated hereby and thereby. All representations, warranties, statements or other communications, whether express or implied, made by Issuer to any Governmental Authority in connection with any Governmental Consents shall be true and correct.

4.5 Litigation. There is no Litigation pending or, to the knowledge of Issuer, threatened against or involving Issuer which questions the validity of this Agreement or any of the Ancillary Documents to which it is a party or seeks to prohibit, enjoin or otherwise challenge Issuer’s ability to consummate the Closing.

4.6 Capitalization & Valid Issuance of Stock Consideration.

1. As of the date hereof, the authorized capital stock of the Company consists of: (i) 300,000,000 shares of Common Stock, par value $0.001 per share, of which 2,868,274 shares are issued and outstanding (the “Common Stock”); and (ii) 5,000,000 shares of Preferred Stock, par value $0.001 per share, of which zero (0) are issued and outstanding (the “Preferred Stock”). In addition, as of the date hereof, there are warrants to purchase 3,880,422 shares of Common Stock (the “Warrants”), options to purchase 12,177 shares of Common Stock (the “Options”) and 6,052 restricted stock units issued and outstanding (the “RSUs” and, collectively, with the Common Stock, Preferred Stock, Warrants and Options, the “Shares”). The Common Stock, Preferred Stock, Warrants, Options and RSUs constitute all of the issued and outstanding equity interests of the Company.
2. Except as set forth in Section 4.6(a), there are no existing options, warrants, calls, rights, subscriptions, arrangements, claims, commitments (contingent or otherwise) or other agreements of any character to which the Company is a party, or is otherwise subject, requiring, and there are no securities of the Company outstanding which, upon conversion, exercise or exchange would require, the issuance, sale or transfer of any additional shares of capital stock or other securities of the Company convertible into, exchangeable or exercisable for or evidencing the right to subscribe for or purchase capital stock or any other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or similar rights with respect to the Company.
3. The Company has reserved 69,979 shares of Common Stock to be issued upon exercise of options or vesting of RSUs to be granted under the Company’s equity incentive plan and 18,229 shares of Common Stock to be issued upon exercise of options or vesting of RSUs currently outstanding under the Company’s equity incentive plan as set forth in Section 4.6(a). Except as set forth in Section 4.6(a), there are no agreements, arrangements or understandings between the Company (or to which the Company is subject), or any other Person relating to the issuance, sale, redemption, transfer, acquisition or other disposition or the registration of the Shares.
4. When issued and delivered in accordance with the terms hereof or the terms of the License Agreement, as applicable, the Closing Stock Consideration or Post-Closing Stock Consideration, as applicable, shall be duly authorized, validly issued, fully paid and nonassessable, free from any liens, encumbrances or restrictions on transfer, including preemptive rights, rights of first refusal or other similar rights.

4.7 Public Filings.

1. All filings made by the Issuer with any Governmental Authority prior to the date hereof are true and correct in accordance with all applicable laws, rules, and regulations as of the date hereof. All filings made by the Issuer with any Governmental Authority after the date hereof shall be true and correct in accordance with all applicable laws, rules, and regulations as of the date of issuance of any Stock Consideration, whether issued pursuant to this Agreement or the License Agreement.
   * 8 -



1. The Issuer has filed or furnished the SEC with all forms, documents and reports required to be filed or furnished by it with the SEC (such forms, documents and reports filed with the SEC, including any amendments or supplements thereto and any exhibits or other documents attached to or incorporated by reference therein, the “Issuer SEC Documents”). As of their respective dates, the Issuer SEC Documents complied in all material respects with the requirements of the securities laws of the United States, and the applicable rules and regulations promulgated thereunder, and none of the Issuer SEC Documents at the time it was filed (or, if amended or supplemented, as of the date of the last amendment or supplement made prior to the date of the execution of this Agreement), contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, or are to be made, not misleading.
2. The financial statements (including all related notes) of the Issuer included in the Issuer SEC Documents fairly present in all material respects the consolidated financial position of the Issuer as at the respective dates thereof and its statements of operations and statements of cash flows for the respective periods then ended (subject, in the case of unaudited interim statements, to normal year-end audit adjustments, none of which would have an Issuer Material Adverse Effect, to the absence of notes and to any other adjustments described therein, including in any notes thereto) in conformity with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q, Form 8-K or any successor form or other rules under the Exchange Act).

**ARTICLE V**

**COVENANTS**

5.1 Public Announcements. The initial press release regarding this Agreement and the Contemplated Transactions shall be made at such time and in such form as Issuer and Buyer agree, provided, that in the event that the Parties cannot agree, either Party shall be permitted to make any disclosure required by Law. Prior to the Closing, none of Issuer or Buyer will issue or make any subsequent press release or public statement with respect to this Agreement or the Contemplated Transactions without the prior consent of the other, except as may be required by Law; provided, that the Party proposing to issue any press release or similar public announcement or communication in compliance with any such disclosure obligations shall use commercially reasonable efforts to consult in good faith with the other Party before doing so.

5.2 Lock-Up and Registration. For a period of: (a) six (6) months from the Closing Date (solely with respect to the Closing Stock Consideration); and (b) six (6) months from the date of issuance of any Post-Closing Stock Consideration (solely with respect to the shares then being issued as Post-Closing Stock Consideration, it being agreed by the Parties that, under this Agreement, stock shall be deemed to be Disposed of on a first in, first out basis), without the prior written approval of Issuer, Buyer shall not Dispose of: (i) any of the Closing Stock Consideration or Post-Closing Stock Consideration, as applicable, together with any shares of Issuer Common Stock issued in respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization; and (ii) any Issuer Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange.

The Issuer will: (A) provide the Buyer the opportunity to participate in: (x) any stock registration conducted by the Issuer under the Securities Act of 1933, as amended, subject to cutbacks by any underwriter; and (y) in any shelf registration conducted by the Issuer; and (B) as demanded by the Buyer from time to time, cause the filing and continued effectiveness of a shelf registration statement with respect to Closing Stock Consideration and Post-Closing Stock Consideration acquired by the Buyer. The Buyer will be responsible for any sales commissions or underwriting fees applicable to the sale of any such shares. The Issuer will also provide to the Buyer the opportunity to join as a party with respect to any of the Closing Stock Consideration and the Post-Closing Stock Consideration, any registration rights agreement to be entered into by the Issuer in the future, on a pari passu basis with the other parties thereto, and in connection therewith will provide to the Buyer a copy of the final version of that agreement at least six (6) Business Days before its execution (and to the extent the Buyer determines to join in such registration rights agreement, it shall be provided with the opportunity to execute that agreement substantially contemporaneously with the time it is being executed by the other parties thereto).

- 9 -



5.3 Solicitation of Issuer Stockholder Approvals.

1. In connection with the Issuer’s 2025 annual meeting of shareholders, Issuer shall prepare and cause to be filed with the SEC a Proxy Statement with respect to approval of, among other items, the issuance of the Subsequent Closing Stock Consideration and the Post-Closing Stock Consideration in accordance with the rules of NASDAQ (the “NASDAQ Proposal”). Each of Issuer and the Buyer shall furnish all information concerning it as may reasonably be requested by the other Party in connection with such actions and the preparation of the Proxy Statement. Issuer will cause the Proxy Statement to be mailed to stockholders of Issuer and shall bear all fees and expenses incurred in connection with the preparation and filing of the Proxy Statement. If such approval by stockholders is not then obtained, the Issuer agrees to hold additional meetings every three months until the NASDAQ Proposal is approved.
2. The Issuer shall use its best efforts to solicit its stockholders’ approval of the NASDAQ Proposal, including, without limitation, by causing: (i) the Issuer’s Board of Directors to recommend to the stockholders of the Issuer that they approve such resolutions (it being represented and warranted by the Issuer that the Board of Directors has already approved and authorized such recommendation); (ii) its officers and directors who hold shares of Issuer Common Stock to be present, either in person or by proxy, at the stockholder meeting for quorum purposes; and (iii) such officers and directors to vote their respective shares of Issuer Common Stock in accordance with the Issuer’s Board of Directors recommendation. The Issuer shall be obligated to use its reasonable best efforts to obtain stockholder approval of the NASDAQ Proposal.

**ARTICLE VI**

**CONDITIONS TO CLOSING**

6.1 Conditions to All Parties’ Obligations.

The obligations of the Parties to consummate the Closing are subject to the fulfillment prior to or at the Closing of each of the following conditions (any or all of which may be waived by the Parties):

1. No Injunction. No Governmental Authority or federal or state court of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, Order or other notice (whether temporary, preliminary or permanent) (collectively, the “Restraints”), in any case which is in effect and which prevents or prohibits consummation of the Closing; provided, that each of the Parties shall use its commercially reasonable efforts to cause any such Restraint to be vacated or lifted; and
2. Delivery. Each of the Parties shall have executed and delivered to one another all of the Ancillary Documents.

6.2 Conditions to Issuer’s Obligations.

The obligations of the Issuer to consummate the Closing are subject to the fulfillment at or prior to the Closing of each of the following conditions (any or all of which may be waived in whole or in part by Issuer):

1. Representations and Warranties. The representations and warranties made by the Buyer (other than the Buyer Fundamental Representations) shall be true and correct in all material respects as of the date hereof and as of the Closing Date, as though made on the Closing Date, except to the extent any such representations and warranties addressed matters as of an earlier date (in which case such representations and warranties shall be so true and correct only as of such earlier date) (and all materiality qualifiers (including Buyer Material Adverse Effect) in such representations and warranties shall be disregarded for purposes of this Section 6.2(a) to prevent an unintended double materiality standard). The Buyer Fundamental Representations shall be true and correct in all material respects as though made as of the date hereof and as of the Closing Date, as though made on the Closing Date, except to the extent any such Buyer Fundamental Representations addressed matters as of an earlier date (in which case such Buyer Fundamental Representations shall be so true and correct only as of such earlier date).
   * 10 -



1. Performance. The Buyer shall have performed or complied with all obligations and covenants hereunder required to be performed or complied with by the Buyer at or prior to the Closing Date.
2. Deliveries. Buyer, shall have delivered to Issuer a certificate executed by Buyer, dated as of the Closing Date, to the effect that the conditions set forth in Section 6.2(a) and (b) have been satisfied;

6.3 Conditions to Buyer’s Obligations.

The obligations of Buyer to consummate the Closing are subject to the fulfillment at or prior to the Closing of each of the following conditions (any or all of which may be waived in whole or in part by Buyer):

1. Representations and Warranties. The representations and warranties made by the Issuer (other than the Issuer Fundamental Representations) shall be true and correct in all material respects as of the date hereof and as of the Closing Date, as though made on the Closing Date, except to the extent any such representations and warranties addressed matters as of an earlier date (in which case such representations and warranties shall be so true and correct only as of such earlier date) (and all materiality qualifiers (including Issuer Material Adverse Effect) in such representations and warranties shall be disregarded for purposes of this Section 6.3(a) to prevent an unintended double materiality standard). The Issuer Fundamental Representations shall be true and correct in all respects, as of the date hereof and as of the Closing Date, as though made on the Closing Date, except to the extent any such Issuer Fundamental Representations addressed matters as of an earlier date (in which case such Issuer Fundamental Representations shall be so true and correct only as of such earlier date).
2. Performance. The Issuer shall have performed or complied with all obligations and covenants hereunder required to be performed or complied with at or prior to the Closing Date.
3. Deliveries. The Issuer shall have delivered to Buyer:
   1. a certificate executed by Buyer’s Representative on behalf of Buyer, dated as of the Closing Date, to the effect that the conditions set forth in Section 6.3(a) and (b) have been satisfied; and
   2. a certificate executed by issuer certifying as of the Closing Date: (A) a true and complete copy of the Governing Documents of the Issuer; (B) true and complete copies of the resolutions of the board of directors of the Issuer authorizing the execution, delivery and performance by the Buyer of this Agreement and the consummation of the transactions contemplated by this Agreement; and (C) incumbency matters; and
   3. a certificate of the Secretary of State or other applicable Governmental Authority certifying the good standing of the Issuer in its jurisdiction of organization as of a date within seven days of the Closing Date.

**ARTICLE VII**

**INDEMNIFICATION; SURVIVAL**

7.1 Indemnification. Each Party agrees to indemnify, defend, and hold the other Party and its and its Affiliates, officers, directors, and employees (each an “Indemnified Person”) harmless from and in respect of any and all Losses, that any of them may incur arising out of, in connection with, relating to or caused by any breach of its representations, warranties covenants or agreements set forth in this Agreement.

- 11 -



7.2 Interest. In addition to any payment required under Section 7.1 (an “Indemnification Payment”), the payor shall also be required to pay to the Indemnified Person entitled to such Indemnification Payment, an additional amount equal to interest on such Indemnification Payment accruing at a rate of 10% per annum (pro-rated per day for any partial period) beginning on the 20th Business Day following the date on which both: (a) such Loss has occurred; and (b) demand for payment in respect thereof in accordance with the terms of this Agreement has been made, through the date of such payment, but only if and to the extent that such Indemnification Payment is required to be paid hereunder.

**ARTICLE VIII**

**TERMINATION**

8.1 Termination. Anything herein or elsewhere to the contrary notwithstanding, this Agreement may be terminated, and the transactions contemplated herein may be abandoned at any time prior to the Closing Date by the mutual written consent of the Parties.

8.2 Effect of Termination. If this Agreement is terminated then the transactions contemplated hereby are and shall be deemed to be, abandoned and this Agreement and all rights and obligations of the Parties hereunder shall terminate without any Liability hereunder of any Party to any other Party, except for the rights, obligations and terms contained in Article IX.

**ARTICLE IX**

**MISCELLANEOUS**

9.1 Amendment. This Agreement may be amended, modified and supplemented in any and all respects only by written agreement of the Issuer and the Buyer with respect to any of the terms contained herein.

9.2 Expenses. All fees and expenses incurred in connection with this Agreement and the Ancillary Documents shall be paid by the Party incurring such expenses, whether or not the transactions contemplated hereby and thereby are consummated.

9.3 Notices. All notices, consents and other communications that are required or may be given pursuant to the terms of this Agreement shall be in writing, and delivery shall be deemed sufficient and shall be deemed to have been duly given as follows: (a) on the actual date of service if delivered personally; (b) at the time of receipt of confirmation by the transmitting Party if by facsimile transmission (provided that no delivery failure message is received by the sender); (c) at the time of receipt if given by electronic mail to the e-mail addresses set forth in this Section 9.3 (provided that no delivery failure message is received by the sender); or (d) on the day after delivery to a nationally recognized overnight courier service during its business hours or the Express Mail service maintained by the United States Postal Service during its business hours for overnight delivery against receipt, and properly addressed as set forth in this Section 9.3:

if to Issuer, to:

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, Texas 77027

Attention: CEO

Telephone No.: (800) 946-9185

E-mail: Notices@CNSPharma.com

- 12 -



with a copy (which copy shall not constitute notice hereunder) to:

ArentFox Schiff LLP

1717 K Street, NW

Washington, DC 20006

E-mail: cavas.pavri@afslaw.com

Facsimile No.: (202) 857-6395

Attention: Cavas Pavri, Esq.; and

if to Buyer, to:

Cortice Biosciences

1345 Avenue of the Americas

42nd Floor

New York, NY 10105

Attn: Michael Weiser/Jason Stein

Email: mweiser@actin.com

Cc: jstein@actin.com

With a copy (which copy shall not constitute notice hereunder) to:

O’Melveny & Myers LLP

Two Embarcadero Center, 28th Floor

San Francisco, CA 94111

Attention: Geoff Kuziemko

Email: gkuziemko@omm.com

Any Party may change its address or other contact information for notice by giving notice to each other Party in accordance with the terms of this Section 9.3. In no event shall delivery to a copied Person alone constitute delivery to the Party represented by such copied Person.

9.4 Governing Law. This Agreement shall in all respects be governed by, and construed in accordance with, the Laws (excluding conflict of laws rules and principles) of the State of Delaware applicable to agreements made and to be performed entirely within such State, including all matters of construction, validity and performance.

9.5 Entire Agreement. This Agreement (including the Buyer Disclosure Schedule, the Issuer Disclosure Schedule, and the other documents and the instruments referred to herein) and the Ancillary Documents constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter of this Agreement and the Ancillary Documents. Any confidential information that is disclosed by one Party to another Party under this Agreement will be governed by the confidentiality and non-use clauses of the License Agreement.

9.6 Severability. Should any provision of this Agreement or the application thereof to any Person or circumstance be held invalid or

unenforceable to any extent: (a) such provision shall be ineffective to the extent, and only to the extent, of such unenforceability or prohibition and shall be enforced to the greatest extent permitted by Law; (b) such unenforceability or prohibition in any jurisdiction shall not invalidate or render unenforceable such provision as applied: (i) to other Persons or circumstances; or (ii) in any other jurisdiction; and (c) such unenforceability or prohibition shall not affect or invalidate any other provision of this Agreement.

- 13 -



9.7 Cumulative Remedies; No Waiver. Except as specifically set forth herein, including Section 9.16 below, the rights and remedies of the Parties to this Agreement are cumulative and not alternative. No failure or delay on the part of any Party in exercising any right, power or remedy under this Agreement shall operate as a waiver of such right, power or remedy, and no single or partial exercise of any such right, power or remedy shall preclude any other or further exercise of such right, power or remedy or the exercise of any other right, power or remedy. To the maximum extent permitted by Law:

1. no claim or right arising out of this Agreement can be discharged by one Party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by the Party or Parties against whom the waiver is to be effective; (b) no waiver that may be given by a Party shall be applicable except in the specific instance for which it is given; and (c) no notice to or demand on one Party shall be deemed to be a waiver of any obligation of that Party or of the right of the Party giving such notice or demand to take further action without notice or demand as provided in this Agreement.

9.8 Parties in Interest; Limitation on Rights of Others. Nothing in this Agreement, whether express or implied, shall be construed to give any Person (other than the Parties hereto and their respective legal representatives, successors and assigns, Indemnified Persons, and as expressly provided herein) any legal or equitable right, remedy or claim under or in respect of this Agreement or any covenants, conditions or provisions contained herein, as a Third Party beneficiary or otherwise.

9.9 Assignability. Neither this Agreement nor any rights or obligations hereunder may be assigned by Issuer without the prior written consent of Buyer. The assignment by Buyer of it this agreement will not relieve Buyer of its obligations hereunder without the prior written consent of the other Parties hereto.

9.10 Disclosure Schedules. The information set forth in the Buyer Disclosure Schedule and the Issuer Disclosure Schedule is disclosed solely for the purposes of this Agreement, and no information set forth therein shall be deemed to be an admission by any Party hereto to any Third Party of any matter whatsoever, including any violation of Law or breach of any Contract. The Buyer Disclosure Schedule and the Issuer Disclosure Schedule and the information and disclosures contained therein are intended only to qualify and limit the representations, warranties and covenants of the Buyer and Issuer, respectively, contained in this Agreement. Nothing in the Buyer Disclosure Schedule or the Issuer Disclosure Schedule is intended to broaden the scope of any representation or warranty contained in this Agreement or create any covenant. Matters reflected in the Buyer Disclosure Schedule and the Issuer Disclosure Schedule are not necessarily limited to matters required by the Agreement to be reflected in the Buyer Disclosure Schedule and the Issuer Disclosure Schedule, respectively. Such additional matters are set forth for informational purposes and do not necessarily include other matters of a similar nature.

9.11 Jurisdiction; Court Litigations; Waiver of Jury Trial; Service of Process.

1. Court Proceedings; Jurisdiction. For the purpose of any Litigation each of the Parties submits to the exclusive jurisdiction of any state or federal court sitting in Delaware in any such Litigation, agrees that all claims in respect of any such Litigation may be heard and determined in any such court and agrees not to bring any action or Litigation arising out of or relating thereto in any other court. Each of the Parties waives any defense of inconvenient forum to the maintenance of any such Litigation so brought and waives any bond, surety or other security that might be required of any other Party with respect thereto.
2. WAIVER OF JURY TRIAL. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW, WHICH CANNOT BE WAIVED, FOR ANY LITIGATION WHICH IS PERMITTED UNDER THIS AGREEMENT TO BE FILED IN A COURT, EACH PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES ANY RIGHT TO A TRIAL BY JURY IN SUCH LITIGATION, INCLUDING LITIGATION TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT OR UNDER ANY AMENDMENT, CONSENT, WAIVER, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION WITH ANY OF THEM OR ARISING FROM ANY RELATIONSHIP EXISTING IN CONNECTION WITH THIS AGREEMENT. EACH PARTY AGREES THAT IN ANY SUCH LITIGATION, THE MATTERS SHALL BE TRIED TO A COURT AND NOT TO A JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY SUCH LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS (a).
   * 14 -



1. Service of Process. Each Party irrevocably consents to the service of summons and complaint and any other process outside the territorial jurisdiction of the courts referred to in Section 9.11(a) hereof in any Litigation by sending or delivering a copy of the process to the Party to be served at the address of the Party and in the manner provided for the giving of notices in Section 9.3 hereof (except that email shall not be a permitted delivery means pursuant to this Section 9.11(c)). Nothing herein shall affect the right of any Party to serve process in any other manner permitted by applicable Law.

9.12 Recovery of Fees by Prevailing Party. In any action at law or in equity to enforce any of the provisions or rights under this Agreement, the Party which does not prevail in such litigation, as determined by the court in a final judgment or decree, shall pay to the prevailing Party all costs, expenses and reasonable attorneys’ fees incurred by the prevailing Party, including such costs, expenses and fees of any appeals. If the prevailing Party shall recover judgment in any action or proceeding, its costs, expenses and attorneys’ fees shall be included as part of such judgment.

9.13 No Other Duties. The only duties and obligations of the Parties under this Agreement are as specifically set forth in this Agreement, and no other duties or obligations shall be implied in fact, Law or equity, or under any principle of fiduciary obligation.

9.14 Reliance on Counsel and Other Advisors. Each Party has consulted such legal, financial, technical or other expert as it deems necessary or desirable before entering into this Agreement. Each Party represents and warrants that it has read, knows, understands and agrees with the terms and conditions of this Agreement.

9.15 Remedies. Subject to Section 9.16, all remedies, either under this Agreement or by Law or otherwise afforded to the Parties hereunder, shall be cumulative and not alternative, and any Person having any rights under any provision of this Agreement will be entitled to enforce such rights specifically, to recover damages by reason of any breach of this Agreement and to exercise all other rights granted by Law, equity or otherwise.

9.16 Post Closing Specific Performance. The Parties agree that irreparable damage would occur in the event that, after the Closing, any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, the Parties agree that, in addition to any other remedies, each Party shall be entitled to enforce the terms of this Agreement, but only following the Closing (but not before) by a decree of specific performance without the necessity of proving the inadequacy of money damages as a remedy. Each Party hereby waives any requirement for the securing or posting of any bond in connection with such remedy. Each Party further agrees that the only permitted objection that it may raise in response to any action for equitable relief is that it contests the existence of a breach or threatened breach of this Agreement. Each Party further agrees that, in the event of any such action for specific performance in respect of such breach or violation, it will not assert the defense that a remedy at law would be adequate or that the consideration reflected in this Agreement was inadequate or that the terms of this Agreement were not just and reasonable.

9.17 Counterparts. This Agreement may be executed in multiple original, PDF or facsimile counterparts, each of which shall be deemed an original, and all of which taken together shall be considered one and the same agreement. Each executed signature page to this Agreement and to each agreement and certificate delivered by a Party pursuant to this Agreement may be delivered by any of the methods described in Section 9.3 hereof, including via facsimile or e-mail, provided that such delivery is effected in accordance with the notice information provided for in Section 9.3 hereof. In the event that any signature to this Agreement or any agreement or certificate delivered pursuant hereto, or any amendment thereof, is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. No Party shall raise the use of a facsimile machine or e-mail delivery of a “.pdf” format data file to deliver any such signature page or the fact that such signature was transmitted or communicated through the use of a facsimile machine or e-mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract and each Party forever waives any such defense.

9.18 Further Assurance. If at any time after the Closing any further action is necessary or desirable to fully effect the Contemplated Transactions, each of the Parties shall take such further action (including the execution and delivery of such further instruments and documents) as any other Party reasonably may request.

- 15 -



9.19 Securities Filings. In the event either Party proposes to file with the SEC or the securities regulators of any state or other jurisdiction: (a) any registration statement or any other disclosure document which describes or refers to the terms and conditions of this Agreement; (b) a copy of this Agreement; or (c) a request for confidential treatment of this Agreement, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing and any related correspondence and/or memorandum, and shall use commercially reasonable efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party requests be kept confidential, and shall only disclose Confidential Information (as defined in the License Agreement) which it is advised by counsel is legally required to be disclosed or required to be disclosed. No such notice shall be required under this Section 9.19 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party.

**Signature page follows**.

- 16 -



IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be duly executed and delivered in its name and on its behalf, all as of the day and year first above written.

**CORTICE BIOSCIENCES, INC.**

By: /s/ Michael Weiser



Name: Michael Weiser

Title: Director

**CNS PHARMACEUTICALS, INC.**

By: /s/ John Climaco



Name: John Climaco

Title: Chief Executive Officer

- 17 -



**Exhibit A**

**License Agreement**

18



**Exhibit 99.1**



**CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies**

*Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM*

*Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date, including clinical trials as monotherapy and in combination with bevacizumab demonstrating encouraging clinical efficacy and safety profile at target therapeutic doses*

*Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM*

*Leveraging the significant clinical infrastructure and deep relationships established with the Neuro-Oncology community to expedite development of TPI 287*

*Company launches new corporate brand and website to more closely align with its unwavering commitment to addressing the most aggressive type of brain cancer, GBM, with an average survival of only 14 to 16 months after diagnosis and no cure*

*Company to host live video webcast to discuss the transaction today, July 30th at 8:30 AM ET*

**HOUSTON, TX (July 30, 2024) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)** ("CNS" or the "Company"), a biopharmaceutical companyspecializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it has entered into an exclusive license agreement with Cortice Biosciences, Inc. (“Cortice”). The Company will host a live webcast presentation to discuss the transaction on Tuesday, July 30, 2024 at 8:30 AM ET (details below). Additionally, CNS announced the launch of its new corporate branding and website, cnspharma.com.

Under the terms of the Agreement, CNS Pharmaceuticals has obtained an exclusive license and the intellectual property rights to TPI 287, a potentially blood brain barrier permeable microtubule inhibitor, currently in development for the treatment of GBM, in exchange for an upfront payment of 616,698 shares of the Company’s common stock, as well as the possibility of future success-dependent milestone payments of cash or the Company’s common stock to Cortice. CNS Pharmaceuticals intends to advance the development of TPI 287 for an oncology indication in the United States, Canada, Mexico, and Japan, which is the territory covered by the Agreement (the “Territory”). Such development efforts will include, but may not be limited to, the prosecution and maintenance of existing and new intellectual property; preclinical and clinical development of TPI 287 including research, manufacturing, laboratory and clinical testing, regulatory filing, and marketing of TPI 287 in the Territory.

John Climaco, CEO of CNS Pharmaceuticals, stated, "For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease.”

1



“Our vision is anchored by our confidence in and commitment to our trial of Berubicin in patients with recurrent GBM. The 252 patients enrolled in its potentially pivotal trial will provide significant data about overall survival compared with Lomustine, the outcome of which will be made public in the first half of next year. Our highly experienced team that created and is executing this trial – currently one of the largest GBM studies being conducted anywhere in the world - makes us uniquely positioned to meet the challenge presented by this disease. The clinical network we have established is unparalleled by any other company’s GBM development program, and as a consequence, the TPI 287 program will require only limited capital resources prior to the release of Berubicin topline data. This will allow us to drive TPI 287 into potential registration studies in the most cost-effective manner possible. After negotiations spanning several years and following extensive scientific and clinical due diligence, we believe the highly compelling safety and efficacy data demonstrated by TPI 287 in over 350 patients to date makes it both the ideal complementary asset to Berubicin and the perfect next step in our Company’s strategic plan. Our work on bringing TPI 287 to patients begins immediately,” added Mr. Climaco.

**TPI 287 Key Highlights**

* TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier (BBB), similarly to Berubicin, TPI 287 has shown the potential to cross the BBB and treat CNS tumors.
* TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent neuroblastoma and medulloblastoma, as well as refractory prostate cancer and melanoma, and in tauopathy disease, which can result in dementia.
* In a multicenter Phase 1 study evaluating TPI 287 in combination with bevacizumab in patients with recurrent GBM, results demonstrated an objective response rate of 60% and disease control rate of 96% in 23 subjects. Progression-free survival (PFS) of 5.5 months and overall survival (OS) of 13.4 months compare favorably to bevacizumab either as monotherapy or in combination with chemotherapy in similar patients yielding PFS of 2-4 months and OS of 6-9 months. The data from this study were recently published in a manuscript titled, “*Phase 1 trial of TPI 287, a* *microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma****1****,”* in *Neuro-Oncology Advances*.
* CNS Pharmaceuticals plans to engage the U.S. FDA and obtain feedback on the design of a study focused on the registration of TPI 287 in recurrent GBM, with the goal of initiating the study in 2025.

Samuel A. Goldlust, MD, Medical Director of Neuro-Oncology at Saint Luke’s Cancer Institute, a former investigator in the Company’s global study of Berubicin, as well as the principal investigator of studies of TPI 287 in GBM added, “The data seen to date with TPI 287 have been highly encouraging. There remains a tremendous unmet need for the GBM patient population, which I believe will require the development of a variety of effective therapeutic approaches. With the promising data demonstrated with both Berubicin and the synergies that TPI 287 has shown, I am excited for the Company to further explore and unlock the potential of TPI 287.”

As previously announced in April 2024, the Company completed enrollment in its global potentially pivotal study evaluating Berubicin for the treatment of GBM. In December 2023 the Company announced the successful completion of its pre-planned interim futility analysis and received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the study without modification. CNS Pharmaceuticals expects to report topline results from its potentially pivotal study of Berubicin in the first half of 2025.



* *Neuro-Oncology Advances*, Volume 6, Issue 1, January-December 2024, vdae009, https://doi.org/10.1093/noajnl/vdae0092



“We also fully understand that the complexity and severity of GBM challenges scientists and clinicians to create novel treatment approaches for brain malignancies. As we have grown our expertise in the development of blood brain barrier permeable chemotherapeutics, we understand that multiple therapeutics may be required to effectively treat these diseases. Combinations of anthracyclines and taxanes that have shown activity for systemic disease may be more powerful as combination agents for the treatment of diseases metastatic to the brain. There is tremendous potential therapeutic synergy between Berubicin and TPI 287, and we are excited to expand our pipeline of drug candidates to offer patients with recurrent GBM an additional brain-penetrative chemotherapeutic option,” added, Sandra Silberman, MD, PhD, Chief Medical Officer of CNS. “Having successfully completed enrollment in our Berubicin study, we have gained extensive experience and expertise in conducting late-stage registrational studies for recurrent GBM. That experience will now inform our clinical strategy for TPI 287 as we engage with key investigators at our active clinical sites. Our investigator network, which took years to build, can now be repurposed to save valuable time and resources, allowing us to expeditiously move forward with a similar potentially registrational study of TPI 287 in 2025.”

**Webcast Details**

CNS Pharmaceuticals will host a live video webcast presentation with members of management and neuro-oncologist and Key Opinion Leader, Dr. Samuel Goldlust for investors, analysts, and other interested parties today, June 30, 2024 at 8:30 a.m. ET to discuss the transaction. Interested participants may register for the event here. The live webcast will be accessible on the Events page of the Investors section of the CNS website, cnspharma.com, and will be archived for 90 days.

**About CNS Pharmaceuticals, Inc.**

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

**Forward-Looking Statements**

**Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements include, without limitation, the Company’s ability to** move forward with a potentially registrational studyof TPI 287 in 2025, **the Company's timing of release of final data from the Berubicin trial expected to occur in the first half of 2025, the ability to** **continue to fund the Berubicin trial to completion and release of final data, and the ability to obtain FDA marketing approval for Berubicin. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.**

**CONTACTS:**

**Investor Relations Contact**

JTC Team, LLC

Jenene Thomas

833-475-8247

CNSP@jtcir.com

3

